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Multiple myeloma (MM) is a haematological malignancy characterised by the clonal 
proliferation of plasma cells (PC) within the bone marrow (BM). While the introduction of 
novel therapies, such as the proteasome inhibitor bortezomib, has greatly improved patient 
outcomes, a subset of patients still does very poorly, due to intrinsic resistance to therapy, 
rapid disease relapse and increased tumour dissemination. However, the mechanisms 
which underpin MM PC dissemination and intrinsic resistance remain poorly understood. 
Our laboratory has previously shown that MM PC expression of the chemokine receptor 
CCR1 is associated with poor prognosis in newly diagnosed patients. In this thesis, the 
mechanisms underlying the prognostic disadvantage of elevated CCR1 expression are 
explored. In addition, the prognostic significance of MM PC expression of other 
chemokine receptors is also investigated.  
 
MM disease development, progression and relapse is dependent on MM PC 
haematogenous dissemination from one bone site to another. Currently, there is little 
understanding of which factors regulate spontaneous dissemination. Our previous studies 
suggested that elevated MM PC CCR1 expression is associated with increased numbers of 
circulating MM PC in newly diagnosed patients. Here, is was found that knockout of 
CCR1 in the MM cell line OPM2 resulted in almost no circulating tumour cells and 
prevented the formation of disseminated tumours following intratibial injection, suggesting 
that CCR1 is critical in egress from the BM to the circulation. In support of this, 
constitutive expression of CCR1 in 5TGM1 MM cells increased the incidence of 
disseminated tumours in C57BL/KaLwRij mice. Furthermore, pharmacological inhibition 
of CCR1 slowed the formation of disseminated tumours in intratibial RPMI-8226 or OPM2 
tumour models. These studies support the further investigation of CCR1 inhibition as a 
therapeutic modality to inhibit MM tumour dissemination. 
  
The poor prognosis associated with CCR1 expression in MM patients suggests that CCR1 
may also play a role in therapeutic resistance. In order to investigate this, the effect of 
CCR1 overexpression and knockdown in MM cell lines on response to bortezomib 
treatment was assessed. CCR1 knockout increased bortezomib sensitivity in vitro and in 
vivo, while constitutive expression of CCR1 decreased bortezomib sensitivity in vitro. 
 
 vii 
Furthermore, RNA sequencing analysis revealed that elevated MM PC CCR1 expression at 
diagnosis or at relapse was associated with poorer overall survival in patients receiving 
bortezomib treatment. Future studies are warranted to assess the ability of CCR1 inhibitors 
to increase response to bortezomib. 
 
In order to investigate the potential role of other chemokine receptors in MM pathogenesis, 
we conducted an in silico analysis to determine the association between chemokine 
receptor expression on MM PCs and overall survival in MM patients. These studies 
identified, for the first time, that elevated CCR10 expression is associated with poor 
prognosis. Notably, elevated MM PC CCR10 mRNA or protein expression was not 
associated with other known prognostic factors in MM patients.   
 
Taken together, these studies suggest that CCR1 is a potential target to enhance response to 
therapy and prevent dissemination of MM PCs. In addition, they suggest that future studies 
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Multiple myeloma (MM) is a plasma cell (PC) malignancy characterised by the presence 
of MM PCs at multiple sites throughout the bone marrow. Increased numbers of peripheral 
blood MM PCs are associated with rapid disease progression, shorter time to relapse and 
are a feature of advanced disease. This poses the opportunity to slow disease progression 
and prevent overt relapse through therapeutic targeting of dissemination. However, the 
mechanisms underlying MM PC dissemination are still incompletely understood, 
highlighting the need for further research to identify the key processes and how to target 
these therapeutically. In this review, the current understanding of the process of MM PC 
dissemination and the extrinsic and intrinsic factors potentially driving it are addressed 
through analysis of patient-derived MM PCs and MM cell lines as well as mouse models 
of homing and dissemination. In addition, we discuss how patient cytogenetic subgroups 
that present with highly disseminated disease such as t(4;14), t(14;16) and t(16;20) suggest 
that intrinsic properties of MM PC influence their ability to disseminate. Preventing 
dissemination may be a beneficial novel therapeutic avenue for patients with high-risk 
cytogenetics and highly disseminated disease.  
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1.2. The role of dissemination in the progression of multiple myeloma 
Multiple myeloma (MM) is an incurable haematological malignancy characterised by the 
uncontrolled proliferation of clonal malignant plasma cells (PCs) in the bone marrow 
(BM).1 Worldwide, MM accounts for 1% of all cancers,2 with approximately 140,000 
people diagnosed with myeloma every year.3 A characteristic feature of MM is that at the 
time of diagnosis, MM PC are present at multiple sites throughout the skeleton.4  
 
During initial disease development, malignant PCs establish themselves in BM niches that 
support their growth.5 Migration and population of these transformed clonal PCs 
throughout the BM leads to the development of the pre-myeloma disease stages 
monoclonal gammopathy of undetermined significance (MGUS) or smouldering MM 
(SMM) and, ultimately, MM. Notably, the detection of multiple tumour lesions (>5mm) 
within the BM is a defining feature of MM, with elevated numbers of MRI-detectable 
lesions being an independent predictor of poor prognosis in newly diagnosed patients, and 
shorter time to progression.6 Furthermore, over two-thirds of newly diagnosed MM 
patients have circulating PC, as detected by flow cytometry,7 cytology8 or slide-based 
immunofluorescence,9 with higher numbers being an independent predictor of shorter 
progression-free survival10,11 and overall survival.7-10 Notably, the association between 
poor outcomes and elevated clonal PC in the PB is independent of BM tumour burden,10 
suggesting an active role for circulating PC in MM disease progression and relapse 
following therapy. Furthermore, the dissemination of MM PCs is a key feature of 
aggressive, advanced forms of MM, including development of extramedullary disease 
(EMD) and plasma cell leukaemia (PCL). PCL is characterised by the presence of very 
high (>20%) numbers of circulating PC.15 Extra-medullary disease (EMD), characterised 
by the dissemination and growth of clonal PCs to soft-tissue sites, occurs in 3-5% of MM 
cases at diagnosis and increases to up to 20% at relapse.16 Importantly, patients with either 
PCL or EMD have a poorer prognosis compared with other MM patients,15 highlighting 
the association between dissemination and aggressive disease.  
 
MGUS and smouldering MM are largely asymptomatic precursor diseases  characterised 
by elevated PC numbers in the BM, an absence of evidence of end organ damage and, 
notably in a lack of multiple MRI-detectable lesions, all of which are characteristic of 
active MM.4 Studies using next generation sequencing examining clonal evolution during 
disease progression from MGUS or SMM to MM suggest that the genetic abnormalities 
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leading to MM are already present at the pre-malignant stages.14,15 These studies suggest 
that the outgrowth of dominant PC clones, and their subsequent population of sites 
throughout the BM, is a key feature of progression to MM. In support of this, increased 
incidence of PB circulating PCs in MGUS and SMM patients is associated with 
progression.18,19 Taken together, these studies suggest that dissemination of clonal PCs is a 
key step for the progression to symptomatic disease.  
 
In this review, we will discuss the current understanding of the mechanisms that underpin 
MM PC dissemination.  Furthermore, we will discuss how this knowledge could be used to 
develop novel therapeutic strategies to delay disease progression and treat high-risk MM 
patients. 
 
1.3. The process of dissemination in MM 
Similar to the process of solid tumour metastasis, the dissemination of MM PCs is 
associated with a loss of their adherence to cells of the BM microenvironment that favours 
MM PC retention, allowing the cells to exit the niche. The tumour cells must then undergo 
trans-endothelial migration, mediated by chemoattractants and adhesive interactions, and 
intravasate (move in the blood from the tissue) where they are carried to a secondary site. 
The tumour cells must then arrest in the BM endothelium and extravasate (move out of the 
blood and into tissues) following chemotactic factors produced by BM cells. The final 
stage of MM PC dissemination is associated with the colonisation of new BM sites which 
supports tumour cell growth.17 The following sections will describe the molecular 
mechanisms that are involved in MM PC dissemination, focusing on both the intrinsic 
properties of the MM PC that support their dissemination, as well as the extrinsic stimuli 
that drive this process. 
 
1.3.1. Retention within the BM stromal niche 
Bone marrow stromal cells (BMSCs) play a critical part in the BM niche that supports the 
growth of MM PC. Adhesion of MM PCs to BMSCs, and extracellular matrix (ECM) 
components that are secreted by these cells, is a crucial mechanism by which MM PCs are 
maintained within the niche (Figure 1.1).17  Binding of the integrin α4β1 (also known as 
very late antigen 4, VLA-4), expressed by MM PCs, to vascular cell–adhesion molecule 1 
(VCAM-1) and fibronectin, expressed by BMSCs, is one of the key factors mediating the 




Figure 1.1. Multiple myeloma plasma cell intravasation is dependent on overcoming 
adhesive interactions within the BM and invading the vasculature basement 
membrane. Release from the stromal niche is likely mediated by both external drivers such 
as hypoxia, and internal drivers in subclones with increased propensity to disseminate. This 
leads to a decrease in multiple myeloma plasma cell (MM PC) expression of key adhesion 
molecules such as α4β1, allowing the MM PC to overcome the retention signal mediated by 
CXCL12 produced by bone marrow stromal cells (BMSCs). Hypoxic MM PC upregulate 
epethelial to mesenchymal transition (EMT)-like genes, decrease their expression of CXCR4 
and increase their expression of CCR1 to mediate mobilisation within the BM niche. 
Upregulation of matrix metalloproteins-2 and -9 then allows invasion into the vasculature 
basement membranes and intravasation into the peripheral circulation during dissemination 





binding to fibronectin decreases the response of MM cell lines to chemotactic factors in 
vitro, supporting its role in MM PC retention.19 Additionally, the integrin αLβ2 complex 
(also known as lymphocyte function-associated antigen 1, LFA-1) on MM PCs mediates 
binding to intracellular adhesion molecule 1 (ICAM-1) on BMSCs.20 Other adhesive 
factors expressed by MM PCs include CD44 variants CD44v6 and CD44v9, which 
mediate adhesion to BMSCs,21 and syndecan-1 (also known as CD138), which is involved 
in adhesion to type 1 collagen.22  
 
The adhesion of MM PCs to BMSCs and ECM can be enhanced by exogenous secreted 
factors which induce rapid cytoskeletal remodelling and conformational changes in 
integrins, thereby increasing adhesion.18,23 The C-X-C chemokine ligand 12 (CXCL12; 
also known as stromal-derived factor-1 [SDF-1]), abundantly produced by BMSCs,24 is the 
ligand for the C-X-C chemokine receptor 4 (CXCR4), expressed universally on MM PCs 
from MM patients.25,26 Treatment of MM PCs with CXCL12 rapidly increases MM PC 
adhesion to fibronectin and VCAM-1 on the surface of BMSCs, through induction of 
conformational changes in integrin α4β1.18 Furthermore, treatment with the CXCR4 
antagonist Plerixafor (also known as AMD3100) rapidly mobilises PCs and stem cells into 
the blood.23,27 Additionally, other factors may increase the adhesion of MM PCs to BMSCs 
by increasing expression of integrins. For example, the cytokine tumour necrosis factor 
alpha (TNF-α), secreted by MM PCs, acts in an autocrine fashion to increase expression of 
the integrin α4β1 and integrin αLβ2 complexes on MM PCs, thereby increasing adhesion 
of MM PC cell lines to BMSCs in vitro.20 In addition, the CD40 ligand (CD40L), 
expressed on haematopoietic cells  binds to the CD40 receptor on MM PCs and stimulates 
the adhesion of MM cell lines to BMSCs and fibronectin in vitro,28,29 via a mechanism 
which may involve upregulation of integrin expression.28 Furthermore, B-cell activating 
factor (BAFF), which is secreted by and expressed on the surface of BMSCs, has also been 
shown to increase the adhesion of MM PCs to BMSCs, although the mechanism involved 
is unclear.30  
 
1.3.2. Release from the BM niche  
To be released from the BM and intravasate into the PB, MM PCs must overcome the 
aforementioned adhesive interactions that act as a strong retention signal (Figure 1.1). 
While the microenvironmental stimuli that regulate the release from the BM niche are 
unclear, decreased expression of key factors involved in adhesion in the stromal niche may 
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play a role. Studies analysing the expression of cell surface adhesion factors in PB PCs 
compared with BM PCs from MM patients have shown that circulating MM PCs express 
less integrin α4β1 compared with BM-resident MM PCs.31,32 In addition, studies show that 
there is a decrease in the activated form of β1 integrin in MM PCs in the PB compared 
with the BM in MM patients,33 suggesting that downregulation of its active form may in 
part facilitate release from the BM. Syndecan-1 expression has also been shown to be 
decreased in PB MM PCs compared with their BM counterparts.31 Notably, MM cell line 
expression of the enzyme heparanase-1, which is responsible for cleaving proteoglycans 
including syndecan-1 from the cell surface, significantly increased the spontaneous 
dissemination of MM cells in vivo, suggesting that shedding of syndecan-1 may promote 
dissemination.34 Finally, PCs from PCL patients have been reported to have decreased 
CD40 expression compared with MGUS PCs, supporting a potential role for loss of CD40 
expression in release of MM PC from the BM niche.35  
 
1.3.3. Microenvironmental control of release from the BM niche 
Release from the BM niche may also be facilitated by signals from the micro-environment 
(Figure 1.1). The BM becomes increasingly hypoxic during MM tumour growth, with 
highly hypoxic regions arising within the tumour mass due to rapid tumour cell growth and 
abnormal blood vessel formation.36 Moreover, the role of hypoxia in tumour progression, 
dissemination and angiogenesis has been demonstrated in mouse models of MM.37-39 In 
particular, Azab and colleagues demonstrated in a mouse model of MM that MM PC 
hypoxia, as assessed by pimonidazole staining, strongly correlated with both BM tumour 
burden and numbers of circulating MM PCs.37 In addition, culturing MM cell lines in 
hypoxic conditions significantly reduced their adherence to BMSCs or to collagen in 
vitro,40 suggesting that hypoxia may play a role in release of MM PCs from the BM 
niche.37 Furthermore, hypoxia has been shown to activate the transcription factors Snail 
and Twist1 that are master regulators of the epithelial to mesenchymal transition (EMT), 
suggesting that, like in epithelial cancers, an EMT-like process may also be occurring in 
MM to allow release from the niche.37 Studies by our group have demonstrated that the 
induction of hypoxia inducible factor HIF-2α in MM cell lines can lead to decreased 
response to stromal cell-derived CXCL12, which may facilitate release from the niche. 
HIF-2α increases CXCL12 expression by MM cell lines41 which, in turn, reduces CXCR4 
cell-surface levels on MM cells,25 forming a feedback loop that leads to a decrease in 
CXCR4 signalling and a desensitisation to exogenous CXCL12.25 In addition, our group 
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has demonstrated that hypoxic activation of HIF-2α leads to upregulation of the C-C 
chemokine receptor 1 (CCR1) in MM PCs, which may also contribute to their preferential 
mobilisation.25 Notably, treatment of CCR1-positive MM cell lines with the CCR1 ligand 
C-C chemokine ligand 3 (CCL3; also known as macrophage inflammatory protein 1 alpha 
[MIP-1 α]) abrogates migration towards CXCL12 in vitro, suggesting that CCL3/CCR1 
signalling can desensitise cells to exogenous CXCL12.25 Taken together, these studies 
suggest that hypoxia may mediate a disruption to the CXCR4/CXCL12 retention signal 
which may allow MM PC release from the BM. 
 
1.3.4. Intravasation 
In order to undergo haematogenous dissemination, following release from the BM stromal 
niche, the MM PCs need to migrate towards the vasculature, and then invade and traverse 
through the basement membranes of the endothelium to intravasate (exit the tissue and 
enter the PB) (Figure 1.1).  
 
BM endothelial cells (BMECs) are sources of secreted factors that are known 
chemoattractants for MM PCs, which may encourage dissemination from the primary site 
into the vasculature. Conditioned media from BMECs has been shown to contain 
chemotactic factors for MM cell lines, including CXCL12 (ligand for CXCR4) and CCL2 
(also known as monocyte chemotactic protein-1 [MCP-1]; ligand for CCR2), which induce 
chemotaxis in MM cell lines and primary MM PCs in vitro.26,42,43 In support of this, 
migration of mouse 5T MM cells towards BMEC conditioned media can be blocked using 
an antibody against CCL2, further suggesting that BMEC-derived CCL2 may promote 
MM PC migration towards the vasculature.42 Collectively, these studies suggest that 
BMECs produce and regulate factors which may dictate the migration of MM PCs towards 
the endothelium and allow intravasation.  
 
In order to intravasate, MM PCs must migrate through and invade the basement 
membranes of the vasculature, which are comprised of type IV collagen, laminin, and other 
ECM components.44 Upregulation of MM PC secretion of specific matrix metalloproteases 
(MMPs), enzymes that degrade ECM components, enable invasion into the vasculature 
(Figure 1.1). MMP-2 and -9, which degrade ECM components including collagen IV and 
laminin, have been implicated in the invasion of MM PC.45,46 Furthermore, osteopontin, 
produced in the BM by fibroblasts, BMECs, osteoblasts, osteoclasts,47 is an inducer of the 
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MM cell line 5T33MM transendothelial migration via upregulation of MMP-9.48 Taken 
together, these studies suggest that increased MMP production in the MM 
microenvironment facilitates invasion of MM PC. 
 
1.3.5. Extravasation and homing to the BM  
In order to exit the the PB and establish within a new site, MM PC need to adhere to the 
endothelial layer and extravasate, in response to local chemoattractant factors, (Figure 1.2). 
MM PC adhesion to BMECs is a critical process during extravasation from the vasculature. 
In the trafficking of lymphocytes, primary, reversible adhesive interactions lead to 
“tethering”, following which the lymphocyte loosely rolls along the endothelium under 
flow conditions, allowing it to sample the vessel for chemokines which drive extravasation 
and homing into the BM (Figure 1.2).49 Tethering of MM PCs and rolling is mediated by 
the binding of P-selectin on the endothelium to the ligands CD44 and P-selectin 
glycoprotein ligand-1 (PSGL-1) on MM PCs.50 Indeed, inhibitors which prevent PSGL-1 
interacting with P-selectin resulted in a reduction of in vivo homing following intravenous 
injection of MM.1S cells.37,51 Furthermore, using  co-injection of 5T cells with an anti-
CD44 antibody resulted in a decrease in 5T cell in vivo homing.51 Studies by our group and 
those of others have also implicated the homophilic adhesion molecule N-cadherin in the 
adhesion of MM PCs to the endothelium. shRNA knockdown of N-cadherin in human and 
murine MM cell lines resulted in a reduction of the adhesion of MM cell lines to BMECs52 
without affecting transendothelial migration in vitro,52,53 suggesting a role for N-cadherin 
in the tethering process, but not in subsequent extravasation. In support of this, N-cadherin 
knockdown or an N-cadherin blocking peptide decreased the homing of MM cells to the 
BM following intravenous injection in mice.52,53  
 
Rolling along the endothelium allows the MM PC to respond to locally produced 
chemokines, in particular CXCL12, which induce strong adhesive interactions through 
stabilising integrin-mediated adhesion to the endothelium and allowing extravasation and 
homing into the BM (Figure 1.2). CXCL12 produced by BMECs has been shown to induce 
rapid activation of integrin α4β1 in primary MM PCs and MM cell lines, enabling arrest of 
the MM PCs through adhesion to BMEC VCAM-1, and subsequently enabling 
transendothelial migration during extravasation.54 Transendothelial migration of human 
myeloma cell lines in vitro54 and in vivo55 and primary MM PC in vitro54 could be 
completely blocked using antibodies against VCAM-1, integrin α4 or integrin β1,  
  
Figure 1.2. Multiple myeloma plasma cell extravasation is dependent on expression of 
key adhesion and chemoattractant molecules. Tethering and rolling are mediated by E- 
and P-selectin expressed on endothelial cells (EC) binding to CD44 and P-selectin 
glycoprotein ligand-1 (PSGL-1) on multiple myeloma plasma cells (MM PCs), respectively 
and homodimerization of N-cadherin. Subsequently, CXCL12 is produced by the 
endothelium, activating MM PC-expressed integrin complex α4β1 allowing arrest through 
firm adhesive interactions with VCAM-1 ligand expressed on EC. Following arrest, MM 
PCs will undergo trans-endothelial migration following chemoattractant factors expressed 
within the bone marrow (BM) by BM stromal cells (BMSCs), macrophages and osteoclasts, 





suggesting a role for integrin α4β1-VCAM-1 interaction in adhesion to BMECs and 
subsequent extravasation.54,55 In support of this, blocking of integrin α4β1 binding with an 
antibody delayed the in vivo homing of the human MM cell line MM.1S to the BM 
following intravenous injection.56 Adhesion to the endothelium57 and exposure to 
CXCL1258 also triggers upregulation of MM PC production of MMP9 which facilitates 
proteolytic degradation of the basement membrane of the endothelium59 to further facilitate 
homing to the BM. 
 
Notably, studies using primary patient samples have demonstrated that CXCR4 is 
upregulated in MM PCs the in the PB compared with the BM,25,60 potentially enabling 
enhanced response to local BMEC-derived CXCL12. The preferential arrest of circulating 
MM PCs in the BM vasculature may, at least in part, be due to the abundant expression of 
CXCL12 by BMECs (Figure 1.2). A murine MM cell line  has been shown to 
preferentially adhere to endothelial cells from the BM, compared with those of other 
organs, suggesting a preference for the BM as a site of establishment.61 60,62Notably, 
Sipkins and colleagues63 have demonstrated that the MM cell line U266, and other B-cell 
lines, preferentially extravasates in the BM at specific vascular regions which express high 
levels of CXCL12 on the surface of the endothelium. 
 
1.3.6. Establishment and colonisation of MM PC in a new BM niche 
Following extravasation, it is thought that MM PC respond to locally produced 
chemokines and growth factors to direct their movement to their ultimate location in the 
BM (Figure 1.2). Recent animal studies from our group71 and those of others,72 have shed 
light on the fate of disseminating clones, and shown that the dissemination process is 
extremely inefficient: of the hundreds of MM cells that may reach the BM following 
intravenous injection, fewer than ten ultimately proliferate to form macroscopic tumours 
while the remaining cells are maintained in a non-proliferative state.64,65 This suggests that 
the BM microenvironment in which the MM PC ultimately resides, may determine 
whether an individual tumour cell is destined for dormancy or proliferation.66,67 At this 
time, it remains unclear whether MM PC are driven by specific microenvironment-derived 
factors to home to specific niches that support their growth, rather than dormancy, or 




The migration of MM PCs towards specific niches in the BM may be driven by a range of 
chemoattractant molecules that are produced by BM cells, including BMSC, osteoclasts 
and macrophages, which play an important role in the MM BM niche (Table 1). For both 
normal PCs and MM PCs, CXCL12 represents the predominant signal that is thought to 
drive homing from the PB into the BM68 and subsequently also leads to CXCL12-mediated 
MM PC retention (described in section 1.3.1).60,62 CXCL12 expression is higher in the BM 
than in the PB,25,60 consistent with its abundant expression by BMSCs,69 establishing a 
gradient that enables homing to the BM. MM PCs have a strong migratory response 
towards CXCL12,70 with CXCL12 inducing cytoskeletal remodelling that enables MM PC 
migration.25,60 Blockade of CXCL12-CXCR4 binding slows homing of human MM cell 
lines from the PB and accumulation in the BM in vivo.60,71 BMSCs also produce the 
hepatocyte growth factor (HGF), which further enhances the chemotactic effect of 
CXCL12 on MM PC.72 Additionally, insulin-like growth factor 1 (IGF-1) has been shown 
to be a promigratory (chemokinetic) and chemoattractant factor for murine73 and human72 
MM cell lines in vitro which synergises with CXCL12 to enhance the response to CXCL12 
in vitro.72 In the mouse MM 5T models, IGF-1 is a critical promoter of homing of MM 
PCs to the BM.73,74 Notably, ablation of macrophages, an abundant source of IGF-1 in the 
BM, is sufficient to inhibit the homing of 5TGM1 cells to the BM.74 Monocytes and 
macrophages also highly express the CCR1 ligand CCL3,74 which is a promigratory factor 
for primary MM PCs and MM cell lines in vitro.70,75 Osteoclasts are also a predominant 
source of a number of promigratory stimuli for MM PC, including CCL3,75 the CCR2 
ligands CCL2, CCL7 (also known as monocyte chemotactic protein-3 [MCP-3]) and CCL8 
(also known as monocyte chemotactic protein-2 [MCP-2])70,75,76 and the CXCR3 ligand 
CXCL10 (also known as interferon gamma-induced protein 10 [IP-10]).70  
 
1.4. Intrinsic MM characteristics that may facilitate dissemination 
It is well-established that there an association between certain chromosomal translocations 
that are frequently observed in MM patients including t(14;16), t(16;20) and t(4;14) and 
the incidence of elevated circulating PC or PCL, suggesting that these chromosomal 
translocations may result in an increased propensity for MM PC dissemination (Figure 
1.3). While t(11;14) is also highly represented in PCL,77 there is no clear gene expression 
signature that could mechanistically explain the increased propensity for dissemination in 
these patients, and as such was not discussed further. As  
Promigratory ligand Receptor Predominant source in the
MM bone marrow
CXCL1065, 94 CXCR3 Osteoclasts and Osteoclast
Precursors95
CXCL1225, 26, 65 CXCR4 Endothelial cells, BMSC,
Osteoclasts26, 96
CCL325, 65, 70 CCR1, CCR5 Osteoclasts, monocytes,
macrophages69, 70
CCL242, 65, 71 CCR2 Endothelial cells, BMSC,
Osteoclasts26, 42, 70, 71, 97
CCL771 CCR2 Osteoclasts70
CCL871 CCR2 Osteoclasts70
IGF167, 69, 98 IGF1R BMSC, Osteoclasts69, 70, 97
HGF67, 99 c-Met BM mesenchymal stem
cells97
Table 1.1. Main sources of promigratory ligands in the MM bone marrow
 
 
Figure 1.3. High-risk cytogenetics are associated with higher numbers of circulating 
multiple myeloma plasma cells in patients. Higher incidences of high-risk cytogenetics 
t(4;14), t(14;16) and t(14;20) occur in patients with high numbers of multiple myeloma 
plasma cells (MM PCs) in the peripheral blood (PB) (33.2%) than in patients with low 
PB MM PCs (12.1%). Patients with plasma cell leukemia (PCL) have the highest 
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discussed below, there is increasing evidence for functional differences arising from 
t(14;16), t(16;20), and t(4;14) translocations which may underlie the propensity for 
dissemination observed in different genetic subtypes of MM.  
 
1.4.1. t(14;16) and t(14;20) 
The chromosomal translocations t(14;16) and t(14;20) lead to constitutive overexpression 
of the transcription factors MAF and MAFB, respectively. Notably, 15% of t(14;16) MM 
patients present with PCL, compared with 1.5% of non-t(14;16) MM patients,78 suggesting 
an association with increased dissemination. The relative infrequency of t(14;20) 
translocations have precluded statistical analysis of the association between MM PC 
dissemination and t(14;20); however, t(14;20) has been reported in 1.3% to 3% of patients 
with elevated PB PC79 and 2.5% of PCL patients,80 compared with 0.8% to 1.0% of MM 
patients,79 suggesting a potentially increased incidence of dissemination in these patients. 
 
Transcriptome profiling has revealed that elevation of expression of two genes, the integrin 
ITGB7 and the chemokine receptor CX3CR1, are highly characteristic of patients and 
human MM cell lines with MAF or MAFB translocations.81,82 Overexpression and siRNA 
knockdown studies have demonstrated that MAF regulates integrin β7 expression in 
human MM cell lines.81 Integrin β7 can form a heterodimer with integrin αE, with the 
αEβ7 complex regulating adhesion to E-cadherin on the surface BMSC.81,83 Blockade of E-
cadherin on BMSC37,81 or of integrin β7 on human MM cell lines81,83 decreases the 
adhesion of MM PC to BMSC in vitro, suggesting that this interaction may play a role in 
adhesion in the niche. Furthermore, shRNA knockdown of integrin β7 decreases the 
migration of human MM cell lines towards CXCL12 in vitro and furthermore, delays BM 
homing following intravenous injection in vivo.83 Elevated integrin β7 expression in MM 
PC may, therefore, contribute to the increased dissemination seen in patients with aberrant 
MAF expression. Microarray data analyses have also shown that expression of the 
chemokine receptor CX3CR1 is a recurrent feature of patients with t(14;16).82 The ligand 
for CX3CR1, CX3CL1, can be released in a soluble form where it can act as a 
chemoattractant, or alternatively, can be presented in a membrane-bound form, where it 
facilitates cell-cell adhesion.84 Notably, CX3CL1/CX3CR1 binding has been implicated in 
playing a key role in the transendothelial migration of lymphocytes by increasing 
endothelial cell adhesion and migration towards chemoattractants.85 While the functional 
role for CX3CR1 in MM PC is unclear, the human MM cell line RPMI-8226 has been 
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shown to bind to CX3CL1 in vitro under shear flow, suggesting that it may play a role in 
adhesion to endothelial cells in MM.86 Gene expression profiling studies have also 
identified elevated expression of IGF1R and CCR1, the receptors for the MM PC 
chemoattractants IGF-1 and CCL3, respectively, are also elevated in t(14;16) human MM 
cell lines and primary MM PCs.81 The expression of these key promigratory receptors may 
also, therefore, play a role in the MM PC dissemination in t(14;16) patients. 
 
1.4.2. t(4;14) 
The chromosomal translocation t(4;14), which leads to constitutive overexpression of the 
histone methyltransferase NSD2 (also known as WHSC1 and MMSET), is also associated 
with high risk disease and increased dissemination in MM patients. The incidence of 
patients with t(4;14) is 2- to 4-fold higher in patients with elevated circulating PCs, 
compared with those with low circulating PCs.79 Additionally, there is some evidence for 
an increase in the incidence of t(4;14) in PCL patients,87 and t(4;14) myeloma is also 
associated with an increased incidence of extramedullary PC tumours.88  
 
Notably, the t(4;14) translocation is associated with an epithelial-to-mesenchymal 
transition (EMT)-like gene expression signature in MM PCs, characterised by upregulation 
of mesenchymal genes, including those for N-cadherin and vimentin, and the transcription 
factor Twist-1.53,89 N-cadherin knockdown studies in MM cell lines have shown that N-
cadherin is important in the homing of MM PCs from the vasculature to the BM.52,53 In 
addition, studies from our group have shown that overexpression of Twist-1 has been 
shown to increase MM PCs dissemination in an intratibial model of MM in vivo.89 
 
Like t(14;16) patients, tumour cells from t(4;14) patients and t(4;14)+ MM cell lines have 
been shown to have increased expression of IGF1R and CCR1 receptors81,90 which may 
also contribute to the increased propensity for dissemination of t(4;14) MM PC. 
 
1.4.3. Subclonal heterogeneity and dissemination  
There is evidence to suggest that, in addition to these chromosomal translocations, other 
secondary chromosomal abnormalities and mutations may increase the ability of individual 
subclones to disseminate.31,91-93 Using FISH or whole exome sequencing on paired BM and 
PB PC samples from MM patients, several studies have found that in some instances 
subclones present in the BM were not present in the PB, and vice versa.31,92,93 However, it 
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remains to be seen whether the subclonal differences observed between the BM and PB in 
MM patients are due to selective microenvironmental pressures, such as hypoxia or other 
as yet uncharacterised stimuli, that drive the efflux of a subclone in a particular 
microenvironment, or if certain secondary copy number changes or SNVs may increase the 
propensity for dissemination in MM, leading to an increased likelihood for dissemination 
of particular subclones. Furthermore, it is also likely that the subclonal differences may be 
due to the inability of single‐site BM biopsy to thoroughly capture the heterogeneity of the 
disease.94 
 
There is some evidence that points to mechanisms whereby certain subclones could have 
an increased propensity for dissemination. Deletion of chromosome 17p13 [del(17p)] 
occurs in approximately 10% of newly diagnosed MM patients.95 Missense mutations in 
TP53, on 17p, are seen in approximately 19% of patients with del(17p), leading to a 
complete inactivation of functional p53.96 There is some evidence for an increased 
incidence of del(17p) in PCL patients,87 although this has not been reported in MM 
patients with elevated PB PC.10 Additionally, Manier et al. identified one patient with 17p 
loss across the BM and PB sample with a TP53 missense mutation which was only 
detectable in the PB sample, suggesting that TP53 mutations may increase the propensity 
for dissemination.93 In support of this, siRNA-mediated knockdown of p53 in NCI-H929 
cells increased their invasion through Matrigel and decreased their adhesion to BMSC in 
vitro.97 Taken together, these studies suggest a potential role for loss of p53 in migration 
and dissemination of MM PC.  
 
1.5. Concluding remarks and future perspectives 
One of the defining features of symptomatic MM is the presence of MM tumours at 
multiple sites in the BM.4 In over two-thirds of newly diagnosed MM patients, circulating 
MM PC are detectable in the PB,9-11 with higher numbers being associated with poorer 
overall survival.9-12 Furthermore, highly disseminated disease, as characterised by elevated 
circulating MM PC and EMD, is a feature of advanced and high-risk disease and is 
associated with poorer overall survival.13,15,78,98 There is also evidence to suggest that 
dissemination of therapy-resistant clones leads to shorter time to relapse, with higher 
numbers of circulating tumour cells at baseline being indicative of shorter progression-free 
survival, regardless of the therapy used.12,13,99,100 These studies suggest that therapies 
which target key processes involved in MM PC dissemination may be useful to delay 
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disease progression or as a maintenance therapy to extend progression-free survival 
following frontline therapy. However, a greater understanding of the mechanisms that 
underpin the dissemination process is needed to reveal potential targets for anti-
dissemination therapy. No anti-dissemination agents have as of yet made it to clinical 
trials, and with promising in vivo results this could present a novel area for the 
development of therapeutics. It remains to be seen, however, whether therapeutic targeting 
of dissemination will translate to a beneficial impact on preventing further MM 
dissemination and controlling disease progression. Some key outstanding questions 
include: What regulates spontaneous dissemination in MM? Which factors promote MM 
PC dissemination to soft tissue sites in advanced disease? Can anti-dissemination therapy 
be clinically useful to slow disease progression and/or prevent the development of overt 
relapse? 
 
In conclusion, this review has highlighted the current understanding of the process of MM 
dissemination. Dissemination is mediated by extrinsic microenvironmental stimuli, the loss 
of adhesive interactions and the increase in chemotactic factors. Furthermore, intrinsic 
changes in MM PCs may also contribute to the propensity to disseminate. Understanding 
the processes of MM PC dissemination may allow the identification of novel therapeutic 
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Multiple myeloma (MM) disease progression is dependent on the ability of MM plasma 
cells (PCs) to egress from the bone marrow (BM), enter the peripheral blood and 
disseminate to distal BM sites. Expression of the chemokine CXCL12 by BM stromal cells 
is crucial for MM PC retention within the BM. However, the mechanisms which overcome 
CXCL12-mediated retention to enable dissemination are poorly understood. We have 
previously identified that treatment with the CCR1 ligand CCL3 inhibits the response to 
CXCL12 in MM cell lines, suggesting that CCL3/CCR1 signalling may enable egress of 
MM PC from the BM. Here, we determined whether CCR1 is a crucial driver of MM PC 
dissemination in vivo. Initially, we demonstrated that expression of CCR1 in the murine 
MM cell line 5TGM1 led to an increased incidence bone and splenic disseminated tumours 
following intratibial 5TGM1 cell injection in C57BL/KaLwRij mice. Furthermore, we 
demonstrated that CCR1 knockout in the human myeloma cell line OPM2 resulted in a 
>95% reduction in circulating MM PC numbers and BM and splenic tumour dissemination 
following intratibial injection in NSG mice. Therapeutic targeting of CCR1 with the 
inhibitor CCX9588 significantly reduced OPM2 or RPMI-8226 MM cell dissemination in 
intratibial xenograft models. Collectively, our findings suggest a novel role for CCR1 as a 
critical driver of BM egress of MM PCs during tumour dissemination. Furthermore, these 
data suggest that CCR1 may represent a potential therapeutic target for the prevention of 




Multiple myeloma (MM) is an incurable haematological cancer characterised by the 
uncontrolled proliferation of clonal plasma cells (PCs) within the bone marrow (BM).1 One 
of the key features of MM is the presence of MM PCs at multiple sites throughout the BM, 
highlighting that dissemination of the transformed PC is a critical process during disease 
development.1,2 In support of this, circulating MM PCs are detectable by flow cytometry in 
approximately 75% of newly diagnosed MM patients.3 Importantly, the presence of 
elevated circulating MM PCs predicting faster time to progression and poorer overall 
survival, independent of BM tumour burden.4-12 
 
The dissemination of MM PCs is a multi-step process requiring release from the supportive 
niche in the BM, intravasation into nearby blood vessels and subsequent extravasation and 
homing to a distal BM site. Integrin mediated adhesion of MM PCs to BM stromal cells 
(BMSCs), and extracellular matrix (ECM) components synthesised by BMSCs, is well-
established to mediate retention of MM PCs within the niche.13 For example, MM PCs 
express the integrin α4β1 (also known as very late antigen 4, VLA-4) that mediates 
adhesion to vascular cell–adhesion molecule 1 (VCAM-1) on BMSCs and to the ECM 
component fibronectin.13 Importantly, the C-X-C chemokine ligand CXCL12 (also known 
as stromal cell-derived factor-1; SDF-1), abundantly produced by BMSCs,14 enhances 
adhesion to fibronectin and VCAM-1 through binding to its receptor CXCR4 on the 
surface of MM PCs and inducing rapid conformational changes of the integrin α4β1 
complex on MM PCs.15 Notably, plerixafor-mediated inhibition of the CXCL12 receptor 
CXCR4 on MM PCs results in mobilization of MM cells to the peripheral blood (PB) in a 
preclinical model of MM.15 These data suggest that CXCL12 is a critical BM retention 
signal for MM PCs and that overcoming the CXCL12/CXCR4 signal may be required for 
release from the niche during dissemination.  
 
In a previous study by Azab and colleagues, increased hypoxia in the BM was shown to be 
associated with an increase in circulating MM PCs in a preclinical model.16 Additionally, 
we have previously identified that overexpression of the hypoxia-inducible factor 2 alpha 
(HIF-2a) in MM cell lines reduces their response to exogenous CXCL12 in vitro, 
suggesting that hypoxia may overcome CXCL12-mediated retention. Furthermore, we 
identified that hypoxia and HIF-2a increased expression of the C-C chemokine receptor 
CCR1 in human MM cell lines (HMCLs).17 CCR1 is a seven-transmembrane G-protein 
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coupled receptor and its most potent activator is CCL3 (also known as macrophage 
inflammatory protein 1 alpha; MIP-1a). Previous literature suggests that MM PCs 
abundantly produce CCL3.18-21 which activates CCR1, expressed on osteoclasts, leading to 
increased osteolysis,19 with inhibition of CCR1 antagonists reducing osteolysis in a murine 
model of MM.22,23 In addition, CCL3 has been shown to be a potent inducer of migration 
of patient-derived MM PCs and MM cell lines in vitro.17,19,20,24 Furthermore, in 
haematopoietic progenitors and natural killer (NK) cells, CCL3/CCR1 signalling drives 
mobilisation from the BM, in part by inactivation of CXCL12/CXCR4.25,26 Similarly, our 
previous studies showed that either pre-treatment of MM cell lines with CCL3 or elevated 
CCR1 expression decreased tumour cell migration towards CXCL12 in vitro.17 Taken 
together, these data suggest that hypoxia-mediated increases in CCR1 expression may 
desensitise cells to CXCL12-mediated BM retention and thereby facilitate dissemination. 
In support of this, we have previously shown that expression of CCR1 in MM PCs is 
associated with poorer prognosis and an increase in the number of circulating MM PCs in 
newly diagnosed MM patients.17 However, a role for CCR1 in the dissemination of MM 
PCs in vivo is yet to be elucidated. Here we determined whether CCR1 overexpression can 
promote tumour dissemination in the syngeneic 5TGM1/KaLwRij murine model of MM. 
Furthermore, using xenograft models of MM, we assessed whether CCR1 knockout limits 
the dissemination of MM PCs in vivo. Lastly, we determined using MM xenograft models 
whether pharmacological inhibition of CCR1 can be used as a viable therapeutic strategy 





All reagents were sourced from Sigma-Aldrich (St Louis, MO) unless otherwise stated. 
Recombinant human (rh)CCL3 was sourced from R&D Systems (Minneapolis, MN). The 
small molecule CCR1 inhibitor CCX9588 was provided by ChemoCentryx (Mountain 
View, CA). For in vitro assays, CCX9588 was prepared at 2mM stock concentrations in 
DMSO and was stored at room temperature until use. Final DMSO concentration in all 
treatment media was 0.01%. For in vivo experiments, CCX9588 was prepared at 7.5mg/mL 
stock concentration in polyethylene glycol (PEG) vehicle and stored at room temperature 
until use.  
 
2.3.2. Cell culture 
All media were supplemented with 2mM L-glutamine, 100U/ml penicillin, 100μg/ml 
streptomycin, 1mM sodium pyruvate and 10mM HEPES buffer, unless otherwise 
specified. The mouse MM cell line 5TGM1-luc (expressing a dual GFP and luciferase 
reporter construct)27 was maintained in Iscove’s modified Dulbecco’s medium (IMDM) 
with 20% foetal calf serum (FCS; HyClone, QLD, Australia) and supplements. HMCLs 
RPMI-8226-luc (expressing GFP/luciferase)28 and OPM2 were maintained in Roswell Park 
Memorial Institute Medium 1640 (RPMI-1640) with 10% FCS and supplements. All cell 
lines were cultured in a humidified environment with 5% carbon dioxide at 37°C.  
 
2.3.3. Generation of 5TGM1 CCR1-expressing cell line 
5TGM1-luc genomic DNA was isolated using a DNeasy Blood and Tissue kit (Qiagen, 
Hilden, Germany) and used for amplification of the murine Ccr1 gene by a nested 
polymerase chain reaction (PCR) using Phusion high-fidelity polymerase (New England 
Biolabs, Ipswich, MA). Primers in the first reaction were designed to flank the Ccr1 
coding sequence with a 5’ BamHI restriction site and the beginning of the human influenza 
hemagglutinin (HA)-tag on the 3’ end (nucleotide sequence of HA-tag: 
TATCCTTATGATGTTCCTGATTATGCT) (Fwd 5’-
GACCGGATCCTCAGCCCACCATGGAGATTTCAGAT-3’; Rev 5’-
TCAGGAACATCATAAGGATAGAAGCCAGCAGAGAGCTCAT-3’). In the second 
reaction, the same forward primer was used, with the reverse primer designed to overlap 
the first reverse primer to complete the HA-tag and add a 3’ NotI restriction site (Rev 5’-
TTGTGCGGCCGCCTAAGCATAATCAGGAACATCATAAGGATA-3’). The HA-tag 
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was used for protein expression confirmation by immunoprecipitation with an anti-HA-tag 
antibody (Catalogue number 05-904, Sigma Aldrich), as previously described,27 and the 
restriction sites enabled cloning into pLeGOiCer2 lentiviral vector29 (gift from Boris 
Fehse; Addgene #27346). 5TGM1-luc cells were infected with lentivirus as previously 
described.30 Briefly, for lentivirus production, HEK293T cells were transfected with 
pLeGOiCer2 or pLeGOiCer2-CCR1 (4µg), and packaging plasmids psPAX2 (4µg; gift 
from Didier Trono (Swiss Federal Institute of Technology Lausanne, unpublished); 
Addgene #12260) and pHCMV-EcoEnV31 (4µg; gift from Miguel Sena-Esteves; Addgene 
#15802) using Lipofectamine-2000 (ThermoFisher). Lentiviral-supernatant was collected 
after 48 hours and 5TGM1-luc cells were infected with supernatant supplemented with 
8µg/mL polybrene (Millipore, Burlington, MA). GFP+Cerulean+ cells were sorted by 
FACS using a FACSAria™ Fusion flow cytometer (BD Biosciences, San Jose, CA) to 
generate a CCR1-expressing (5TGM1-CCR1) or EV control (5TGM1-EV) cell line.  
 
2.3.4. Generation of OPM2 CCR1-knockout cell lines 
CCR1 knockout (KO) cell lines were generated using a lentiviral two-vector CRISPR-Cas9 
system consisting of a Cas9 constitutive expression vector with an mCherry reporter 
(FuCas9Cherry; gift from Marco Herold, Addgene plasmid #7018)32 and a doxycycline-
inducible sgRNA expression vector with an eGFP reporter (FgHtUTG; gift from Marco 
Herold, Addgene plasmid #70183) 32 An mPlum FgH1tUTP vector was generated by 
digestion of the FgH1tUTG vector with BlpI and ClaI to excise the egfp gene, which was 
replaced with a synthesised mplum gBlock gene fragment (Integrated DNA Technologies, 
Newark, NJ) using isothermal assembly. Two CRISPR strategies were used 
(Supplementary Figure 2.1). The MIT CRISPR design software was used for the design of 
the sgRNAs (http://crispr.mit.edu). sgRNAs were designed to either flank the human 
CCR1 coding exon to delete the exon (sgRNA-A and sgRNA-B), or to target key tyrosine 
residues located in the ligand-binding domain (sgRNA-C). For cloning of individual 
sgRNAs, 24-bp oligonucleotides were synthesised (Sigma-Aldrich) including the sgRNAs 
sequences (gRNA-A 5’-GTTAGACTAAGATTCCTAGA-3’; gRNA-B 5’-
GAGGGAATGTAATGGTGGCC-3’; gRNA-C 5’-GCCATGTGTAAGATCCTCTC-3’) 
and 4-bp overhang for the forward (TCCC) and reverse (AAAC) oligonucleotides to 
enable cloning into the BsmbI site of the FgHtUT vectors. 
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OPM2 cells were first infected with FuCas9mCherry and FACS sorted for mCherry+ cells 
(OPM2-Cas9) using a FACSAria™ Fusion flow cytometer. To generate empty vector 
control lines, OPM2-Cas9 cells were infected with the FgH1tUTG or FgH1tUTP vectors, 
alone, were sorted for mCherry+GFP+ (OPM2-EV-1) or mCherry+mPlum+ (OPM2-EV-2) 
cells, respectively. To generate gRNA-expressing cells, OPM2-Cas9 cells were either co-
infected with the FgH1TUTG-sgRNA-A and FgH1TUTG-sgRNA-B vectors or were 
infected with the FgH1TUTP-gRNA-C vector alone.  
For isolation of the clonal OPM2-CCR1-KO-1 cell line, OPM2-Cas9 cells transfected with 
FgH1TUTG-sgRNA-A and FgH1TUTG-sgRNA-B vectors were sorted into 96-well plates 
using a FACSAria™ Fusion flow cytometer for single cell analysis. Clones were 
subsequently screened to identify CCR1-negative clones. Briefly, 1x105 cells per test were 
stained with an anti-CCR1 mouse monoclonal antibody (clone 53504; R&D Systems) or an 
in-house IgG2B isotype control antibody (1A6.11), followed by a goat anti-mouse 
biotinylated secondary antibody (Southern Biotech, Birmingham, AL), followed by a 
BV421-conjugated streptavidin tertiary antibody (BD Biosciences, North Ryde, Australia). 
Cells were analysed using a LSRFortessa flow cytometer (BD Biosciences). Genomic 
DNA from the CCR1-negative clones was isolated using a DNeasy kit and 35 cycles of 
PCR was conducted using primers designed to flank the first coding exon of human CCR1 
(Fwd 5’-TGGGGTTGACCTACTAGGATT-3’; Rev 5’-
TCGCTGCAATAAAGCCATTAG-3’) and the products subjected to agarose gel 
electrophoresis to identify whole exon deletions (Supp. Figure 2.1B). Gel purified PCR 
products were subjected to Sanger sequencing (AGRF). This identified a clonal 
homozygous KO CCR1 cell line (OPM2-CCR1-KO-1) (Supp. Figure 2.1C).  
For isolation of the non-clonal OPM2-KO-2 cell line, OPM2-Cas9 cells transfected with 
FgH1tUTP-gRNA-C vector were stained with antibodies against CCR1, as described 
above, and sorted on the basis of mPlum+mCherry+BV421- to isolate a CCR1-knockout 
population (OPM2-CCR1-KO-2). Mutagenesis was confirmed in the OPM2-CCR1-KO-2 
line by conducting 35 cycles of PCR using primers flanking the CCR1 ligand binding 
domain (Fwd 5’-GCCTTTAGTAGCAGAGTAAAGACA-3’; Rev 5’-
CCAGCCCAAAGAGGTTCAGTT-3’). Reannealed PCR products were subjected to 
heteroduplex analysis by resolution on a 1xTBE polyacrylamide gel (Supp. Figure 2.1E). 
 
2.3.5. Quantitative real time PCR (qPCR) 
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Total RNA was isolated using TRIzol reagent (Thermofisher, Waltham, MA) and DNase 
treated using RQ1 DNase as per the manufacturer’s instructions (Promega, Madison, WI). 
cDNA was synthesized using Superscript IV First-Strand Synthesis System 
(Thermofisher). Real-time qPCR was performed using a CFX Connect 9000 Real-Time 
PCR machine (BioRad, Hercules, CA) using primers for murine Ccr1 (Fwd 5’-
GTGGTGGGCAATGTCCTAGT-3’; Rev 5’-AGAAGCTTGCACATGGCATC-3’) and 
Actb (Fwd 5’ -GATCATTGCTCCTCCTGAGC-3’; Rev 5’-GTCATAGTCCG 
CCTAGAAGCAT-3’). Changes in gene expression were calculated relative to Actb using 
the 2-ΔΔCt  method.33 
 
2.3.6. Transwell migration assays 
For HMCLs, cells (1×105) were washed once in RPMI-1640 with 1% FCS and were 
seeded in 8µm transwells (Costar) in triplicate and cell migration towards rhCCL3 
(100ng/mL) in RPMI-1640 with 1% FCS, or RPMI-1640 with 1% FCS alone (untreated 
controls) was assessed after 18 hours as previously described.17 Where indicated, cells 
were treated with CCX9588 (100nM-1µM) or vehicle control for 24 hours, then washed 
once in RPMI-1640 with 1% FCS and resuspended in RPMI-1640 with 1% FCS 
containing CCX9588 prior to seeding into transwells. For the murine MM PC cell line 
5TGM1, cells (5x105) were washed once in IMDM with 1% FCS and were seeded in 
transwells in IMDM with 1% FCS in triplicate and cell migration towards IMDM with 
20% FCS and rhCCL3 (100ng/mL) or IMDM and 20% FCS alone (untreated controls) was 
assessed after 24 hours using a luciferase assay, as previously described.27 Percentage cell 
migration is represented as normalized to the untreated controls.  
 
2.3.7. Proliferation assays 
Cells were plated at 1x105 cells/mL in triplicate in phenol red-free IMDM containing 20% 
FCS and supplements (5TGM1) or phenol red-free RPMI-1640 containing 10% FCS and 
supplements (OPM2-EV-1 and RPMI-8226-luc) with or without addition of rhCCL3 
(100ng/mL) or CCX9588 (0.1nM-1µM) or vehicle, in a 96-well plate. Cell numbers were 
assessed over 72 hours using WST-1 reagent (Roche, Basel, Switzerland) as previously 
described.34 
 
2.3.8. Western blotting 
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For CCL3 stimulation experiments, OPM2-EV-1 or RPMI-8226-luc cells were treated with 
CCX9588 (10nM-10µM) or vehicle (0.01% DMSO) for 24 hours in serum-free RPMI-
1640 containing supplements. Cells were stimulated with rhCCL3 (100ng/mL) for 5 min 
and cell lysates were prepared as previously described.35 Proteins (50µg) were resolved 
under reducing conditions on 10% SDS-PAGE gels and transferred to 0.45µm 
nitrocellulose membranes. Immunoblotting was performed with the following antibodies: 
phosphorylated Akt (Ser473), total Akt, phosphorylated Erk1/2, total Erk1/2 (Cell 
Signaling Technologies, Danvers, MA, USA; all at 1:1000) and Hsc70 as a loading control 
(Enzo, Farmingdale, NY, USA, 1:1000). Membranes were developed using Dylight™-680 
or 800 conjugated secondary antibodies (1:20,000; Invitrogen, Carlsbad, CA) and 
visualised using the Odyssey Infrared Imaging system (LI-COR Bioscience, Lincoln, NE, 
USA). 
 
2.3.9. C57BL/KaLwRij murine model of MM 
C57BL.KaLwRijHsd (KaLwRij) mice were bred and housed at the South Australian 
Health and Medical Research Institute (SAHMRI) Bioresources facility. All animal studies 
were approved by and performed in accordance with the SAHMRI Animal Ethics 
Committee (ID #356). Five- to six-week-old female KaLwRij mice were inoculated into 
the left tibia with 1x105 5TGM1-CCR1 or control 5TGM1-EV cells in 10µL phosphate-
buffered saline (PBS). After 3.5 weeks, mice were injected with firefly D-luciferin 
(150mg/kg, diluted in PBS, 100µL i.p.), anaesthetised and after 15 min PB was collected 
by cardiac puncture. Mice were then humanely killed, and spleens were dissected and 
immediately imaged using bioluminescent imaging (Xenogen IVIS 100; Perkin Elmer). 
Bioluminescence signal below background (2000 p/sec/cm2/sr) was classified as not 
detectable. PB was subjected to red cell lysis as described previously36 and resuspended in 
PFE prior to analysis of GFP+ cells on a FACSCanto II flow cytometer (BD Biosciences). 
Injected tibiae, and tibiae and femora from the contralateral leg, were excised and BM was 
flushed with 10mL PBS + 2% FCS + 2mM EDTA (PFE) and resuspended in 1mL PFE for 
analysis of GFP+ cells on a LSRFortessa flow cytometer. GFP+ tumour cells of total viable 
mononuclear (parent) cells below 0.01% was defined as not detectable.  
 
2.3.10. NSG murine model of MM 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)37 mice were bred and housed at the SAHMRI 
Bioresources facility. All animal studies were approved by and performed in accordance 
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with the SAHMRI Animal Ethics Committee (ID #286). Female NSG mice (5-6 weeks 
old) were inoculated into the left tibia with 5x105 OPM2-EV-1 or OPM2-CCR1-KO-1 
cells in 10µl PBS. After 28 days, long bones and PB were isolated and analysed as 
described above. Spleens were excised, photographed and measured and were fixed in 10% 
neutral buffered formalin and paraffin embedded prior to immunohistochemistry analysis 
as described below.  
 
For CCR1 inhibition studies with the CCR1 small-molecule inhibitor CCX9588, mice were 
treated twice daily (12-hour intervals) via oral gavage with either CCR1 antagonist 
CCX9588 (15mg/kg) or PEG vehicle alone commencing 3 or 14 days after tumour-cell 
injection until day 28 at experimental endpoint. Tumour burden, circulating tumour cells 
and soft tissue and bone dissemination was assessed at day 28, as described above. For 
mice treated from day 3 post-tumour cell injection, blood from terminal cardiac bleeds was 
also used for performing total blood counts using a HEMAVET 950 automated blood 
analyser (Drew Scientific, Miami Lakes, FL, USA), and serum analysis of trough (12 
hours after final dose) CCX9588 levels by liquid chromatography/mass spectrometry at 
Chemocentryx (Mountain View, CA). 
 
2.3.11. Immunohistochemistry 
Tumour cells in paraffin-embedded sections (5µm) were immunostained using a goat 
polyclonal anti–GFP antibody (Rockland, Pottstown, PA), biotinylated anti-goat secondary 
antibody (Vector Laboratories, CA, USA) followed by incubation with streptavidin-HRP 
(Vector Laboratories) and DAB (Vector Laboratories) as previously described.38 2.3.12.  
 
2.3.12. Statistical Analyses 
Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software Inc., San 
Diego, CA, USA). In vitro assays were analysed using unpaired t-test for comparisons 
between cell lines, two-way ANOVA with Sidak’s multiple comparisons test for migration 
assays, or one-way ANOVA with Tukey’s multiple comparisons test for WST-1 and 
viability assays. In vivo experiments were analysed using a Mann-Whitney U test for PB 
and BM tumour burden, one-way ANOVA with Tukey’s multiple comparisons test for 





2.4.1. Expression of CCR1 in the mouse MM cell line 5TGM1 does not affect 
proliferation in vitro and increases incidence of splenic and bone dissemination in vivo 
Based on our previous study showing that hypoxic MM PCs upregulate expression of 
CCR1 and decrease their response to CXCL12 in vitro,17 we hypothesised that hypoxia-
mediated elevations in CCR1 expression drive the dissemination of MM PCs in vivo. 
Initially, we assessed whether constitutive expression of CCR1 affected the migration and 
dissemination of the mouse MM cell line 5TGM1 which does not express detectable CCR1 
basally (Figure 2.1A), and exhibits low levels of spontaneous dissemination in vivo.30 
Expression of functional HA-tagged CCR1 was confirmed by qPCR and by 
immunoprecipitation/Western blotting (Figure 2.1A, B) and by the ability of the 5TGM1-
CCR1 cells to migrate towards rhCCL3 in a transwell assay (percent increase in migration 
over controls: 44.2 ± 8.95% [mean ± SEM]; p<0.01; Figure 2.1C). Expression of CCR1 
did not affect the proliferation of 5TGM1 cells, relative to EV controls, either basally 
(p=0.63; Figure 2.1D) or following addition of rhCCL3 (p=0.99; Figure 2.1E) over a 72-
hour time course. 
 
To investigate whether CCR1 expression increased the dissemination of 5TGM1 cells in 
vivo, 5TGM1-CCR1 or EV cells were intratibially injected into C57BL/KaLwRij mice. 
Primary tumour burden in the injected tibiae was not significantly different between 
animals injected with 5TGM1-CCR1 cells and mice injected with 5TGM1-EV cells 
(p=0.82; Figure 2.2A). Similarly, the numbers of circulating MM cells in the PB or the 
tumour burden in the contralateral leg were also not significantly different between groups 
(p=0.62 and p=0.41, respectively; Figure 2.2B, C). However, there was a significant 
increase in the number of mice with disseminated tumour cells in the 5TGM1-CCR1 
group, with 8/11 mice (73%) in this group having detectable GFP+ cells in the contralateral 
leg, compared with 4/11 mice (36%) injected with 5TGM1-EV cells (p<0.0001; Figure 
2.2D). Furthermore, an increase in the incidence of dissemination to the spleen was also 
observed in the 5TGM1-CCR1 group, with 9/11 mice (82%) having tumour detectable in 
the spleen by bioluminescence imaging, compared with 4/8 mice (50%) in the 5TGM1-EV 
cohort (p<0.0001; Figure 2.2E, F). Collectively, these data suggest that expression of 

















































Figure 2.1. CCR1 expression in 5TGM1 murine MM cell line increases migration 
towards CCL3 but does not affect proliferation. A. Expression of murine Ccr1 
mRNA was confirmed in 5TGM1-CCR1 cells by real-time PCR. B. CCR1-HA protein 
expression in 5TGM1-CCR1 cells was confirmed by immunoprecipitation using an 
anti-HA antibody followed by Western blotting with anti-HA antibody. A 
representative of two independent experiments is shown. C. Migration of 5TGM1-
CCR1 and empty vector control (EV) cells towards 100ng/mL rhCCL3 was assessed 
in a transwell assay after 24 hours. D. Relative number of 5TGM1-CCR1 and -EV 
cells was assessed over 72 hours by WST-1 assay. E. Relative number of 5TGM1-
CCR1 and -EV cells was assessed by WST-1 assay following 72 hours of culture with 
or without addition of 100ng/mL rhCCL3. Graphs depict mean ± SEM of three 
biological replicates (A) or three or more independent experiments (C-E). **p<0.01, 
****p<0.0001, unpaired t-test (A), two-way ANOVA with Sidak’s multiple 















































































































































































Figure 2.2. CCR1 expression in 5TGM1 MM PCs increases incidence of bone and 
splenic dissemination in a C57BL/KaLwRij intratibial model of MM. A. Primary 
tumor burden in injected tibiae after 3.5 weeks in C57BL/KaLwRij mice injected with 
5TGM1-CCR1 or control 5TGM1-EV cells. Percentage of GFP+ MM cells of total 
mononuclear cells were quantitated using flow cytometry. B. Number of circulating 
5TGM1-CCR1 or -EV cells in peripheral blood of mice, as assessed by flow 
cytometry. C. Tumor burden disseminated to the non-injected contralateral leg in mice 
injected with 5TGM1-CCR1 or -EV cells, as assessed by flow cytometry. D. 
Proportion of mice with detectable GFP+ MM cells in the contralateral long bones, as 
assessed by flow cytometry. E. Spleens were collected from 8 mice (5TGM1-EV) and 
11 mice (5TGM1-CCR1) and imaged using bioluminescence imaging, with 
representative spleens from each group shown. F. Proportion of mice with detectable 
bioluminescence signal in the spleen. Box and whisker plots depict median and 







































































































































2.4.2. Knockout of CCR1 in the HMCL OPM2 does not affect proliferation in vitro 
and prevents dissemination in vivo. 
To further investigate the role of CCR1 in tumour dissemination in MM, we generated 
CRISPR/Cas9-mediated CCR1 knockouts in the HMCL OPM2 (Supplementary Figure 
2.1). Loss of protein expression in OPM2-CCR1-KO-1 and OPM2-CCR1-KO-2 cell lines 
was confirmed by flow cytometry (Figure 2.3A). Furthermore, migration of OPM2-EV-1 
and -2 cell lines towards rhCCL3 (OPM2-EV-1: 134.9 ± 14.5% increase in migration, 
p<0.01; OPM2-EV-2: 150.0 ± 20.6% increase in migration, p<0.01) was not observed in 
the OPM2-CCR1-KO cell lines (Figure 2.3B). Basal proliferation of OPM2 cell lines was 
unaffected by CCR1 knockout, as assessed over a 72-hour time-course (OPM2-KO-1: 
p>0.99, Figure 2.3C; OPM2-KO-2: p=0.98, Figure 2.3D). Furthermore, the addition of 
rhCCL3 did not affect proliferation of CCR1 KO or EV cell lines after 72 hours (OPM2-
KO-1: p=0.54; OPM2-KO-2, p=0.61, Figure 2.3E). 
 
To determine if CCR1 knockout limited MM PC dissemination in vivo, NSG mice were 
injected with either control (OPM2-EV-1) or CCR1 KO (OPM2-CCR1-KO-1) cells. 
Knockout of CCR1 reduced primary tumour burden by 45.5%, compared with mice 
inoculated with OPM2-EV-1 cells (p<0.01; OPM2-EV-1: 77.2 ± 7.60% of total parent 
population [mean ± SEM]; OPM2-KO-1: 42.1 ± 10.6%), after 4 weeks (Figure 2.4A). 
Circulating tumour cell numbers were significantly reduced by 97.8% in mice bearing 
CCR1 knockout cells compared with EV controls (p<0.0001; OPM2-EV-1:1.39 ± 0.305% 
of total parent population [mean ± SEM]; OPM2-KO-1: 0.0304 ± 0.0201%; Figure 2.4B). 
Additionally, dissemination of OPM2 cells from the primary tumour to the contralateral 
leg was observed in OPM2-EV-1 bearing mice but not in mice bearing OPM2-CCR1-KO-
1 cells, with a 99.9% reduction in BM disseminated tumour cells (p<0.0001; OPM2-EV-
1:49.5 ± 7.52% of total parent population [mean ± SEM]; OPM2-KO-1: 0.02 ± 0.005%; 
Figure 2.4C). Similar results were seen in the development of splenic disseminated 
tumours, with mice inoculated with OPM2-EV-1 cells developing splenomegaly (Figure 
2.4D) from tumour cell infiltration, as confirmed by immunohistochemistry for GFP+ cells 
(Figure 2.4E), which was markedly reduced in mice inoculated with OPM2-CCR1-KO-1 
cells (p<0.0001; naïve controls: 1.07 ± 0.0413 cm in length [mean ± SEM]; OPM2-EV-1: 

















































Figure 2.3. Knockout of CCR1 in human OPM2 MM PCs decreases migration 
towards CCL3 and does not affect proliferation. A. CRISPR-Cas9-mediated 
knockout of CCR1 was confirmed in OPM2-CCR1-KO-1 and OPM2-CCR1-KO-2 cells 
by flow cytometry following staining with an anti-hCCR1 antibody or isotype control. 
B. Migration of OPM2-CCR1-KO-1 and OPM2-CCR1-KO-2 cells and EV control cells 
towards 100ng/mL rhCCL3, or media alone, was assessed in a transwell assay after 18 
hours. Migration is expressed relative to no chemoattractant controls. C. Relative 
numbers of OPM2-CCR1-KO-1 or OPM2-EV-1 control cells, were assessed over 72 
hours by WST-1 assay. D. Relative numbers of OPM2-CCR1-KO-2 or OPM2-EV-2 
control cells, were assessed over 72 hours by WST-1 assay. E. The effect of 72 hours 
of treatment with 100ng/mL rhCCL3 on relative numbers of OPM2-CCR1-KO-1 and 
OPM2-CCR1-KO-2, and EV-1 and EV-2 control cells was assessed by WST-1. Graphs 
depict mean ± SEM of three or more independent experiments (A-E). **p<0.001, two-
















































































































































































Figure 2.4. Dissemination of human multiple myeloma cell line OPM2 in NSG mice 
is abrogated by knockout of CCR1. A. Primary tumor burden in injected tibiae after 
4 weeks in NSG mice injected with OPM2-EV-1 or OPM2-KO-1 cells. B. Number of 
circulating OPM2-EV-1 or OPM2-KO-1 cells in peripheral blood of mice, as assessed 
by flow cytometry. C. Tumor burden disseminated to the non-injected contralateral leg 
in mice injected with OPM2-EV-1 or OPM2-KO-1 cells, as assessed by flow cytometry. 
D. Length of spleens collected from naïve NSG mice (n=7 mice) or mice bearing OPM2-
EV-1 (n=3 mice) or OPM2-KO-1 (n=3 mice) cells were measured. Image of spleens of 
OPM2-EV-1- or OPM2-CCR1-KO-1-bearing mice. Scale bar: 10 mm E. Splenic tumor 
cell infiltration in mice bearing OPM2-EV-1 or OPM2-CCR1-KO-1 cells was 
confirmed by immunohistochemistry with an anti-GFP antibody (brown). Percentage of 
GFP+ MM cells of total mononuclear cells were quantitated using flow cytometry (A-
C). Representative flow plots of one mouse per group are shown (B-C).  A 
representative of 5 mice/group is shown; scale bar: 20 µm (E). Box and whisker plots 
depict median and interquartile range, n = 9-10 mice/group. **p< 0.01, ****p< 0.0001, 






























































































































































2.4.3. The CCR1 inhibitor CCX9588 inhibits CCR1 downstream signalling and 
migration towards CCL3 in vitro 
Next, the effects of a selective small molecule CCR1 inhibitor, CCX9588, on MM cells 
was assessed in vitro. To investigate whether the small molecule CCR1 inhibitor CCX9588 
effects cell survival and/or proliferation, CCR1-expressing OPM2-EV-1 or RPMI-8226-
luc17 cells were cultured with increasing concentrations of CCX9588 or vehicle alone for 
72 hours. Neither OPM2-EV-1 cell number (p=0.88, Figure 2.5A) or viability (p=0.70, 
Figure 2.5B) were affected by treatment with up to 1µM CCX9588. However, there was a 
35% decrease in cell number in RPMI-8226-luc cells treated with 1µM CCX9588 (p<0.01, 
Figure 2.5C), while cell survival was unaffected by up to 1µM CCX9558 (p=0.50, Figure 
2.5D), suggesting that this concentration may decrease cell proliferation of these cells. 
Based on these results, concentrations up to 100nM and 1µM were used for further 
characterisation in RPMI-8226-luc and OPM2 cells, respectively. 
 
To investigate the anti-CCR1 function of CCX9588, OPM2-EV-1 or RPMI-8226-luc cells 
were treated with CCX9588 or vehicle alone in serum-free media for 24 hours and were 
then stimulated with rhCCL3 for 5 min prior to generating cell lysates. Western blot 
analysis showed that CCL3 treatment induced AKT and ERK1/2 phosphorylation in 
OPM2-EV-1 cells, which was inhibited by 10nM CCX9588 or higher (Figure 2.5E). While 
an increase in ERK1/2 phosphorylation was not detectable in RPMI-8226-luc cells 
following CCL3 stimulation, p-AKT was increased by CCL3 and this was inhibited by 
10nM or higher CCX9588 pre-treatment (Figure 2.5F). In order to characterise the ability 
of CCX9588 to inhibit CCR1 function, OPM2-EV-1 or RPMI-8226-luc cells were pre-
treated with CCX9588 (1µM or 100nM, respectively) for 24 hours prior to conducting a 
transwell migration assay. Pre-treatment of OPM2 or RPMI-8226 cells with CCX9588 
resulted in a complete inhibition of migration towards rhCCL3 (OPM2: p<0.001, Figure 
2.5G; RPMI-8226: p<0.01, Figure 2.5H). 
 
2.4.4. CCX9588 treatment reduces dissemination of MM PCs in vivo  
To investigate the effectiveness of CCR1 inhibition in suppressing MM PC dissemination 
in vivo, the effects of the CCR1 inhibitor CCX9588 were assessed in NSG mice bearing 
OPM2-EV-1 or RPMI-8226-luc cells. CCX9588 treatment did not have appreciable 

















































Figure 2.5. CCX9588 treatment prevents activation of CCR1 signalling in MM PCs 
and their migration towards CCL3 in vitro. A. Relative number of OPM2-EV-1 cells 
was assessed after 72 hours of treatment with 10nM-1µM CCX9588 (all containing 
0.01% DMSO), or 0.01% DMSO vehicle alone. B. Viability of OPM2-EV-1 cells was 
assessed after 72 hours of treatment with 10nM-1µM CCX9588 (all containing 0.01% 
DMSO), or 0.01% DMSO vehicle alone. C. Relative number of RPMI-8226-luc cells 
was assessed after 72 hours of treatment with 10nM-1µM CCX9588 (all containing 
0.01% DMSO), or 0.01% DMSO vehicle alone. D. Viability of RPMI-8226-luc cells 
was assessed after 72 hours of treatment with 10nM-1µM CCX9588, or 0.01% DMSO 
vehicle. E. OPM2-EV-1 cells were treated with CCX9588 (10nM-1µM) or media alone 
for 24 hours, and cells were stimulated with 100ng/mL rhCCL3 for 5 minutes. Cells 
were lysed and Western blotting was performed with antibodies against p-Akt, p-
ERK1/2, total AKT and total ERK. Hsc70 was used as a loading control. A 
representative of 3 experiments is shown. F. RPMI-8226-luc cells were treated with 
CCX9588 (10nM-1µM) or media alone for 24 hours, and cells were stimulated with 
100ng/mL rhCCL3 for 5 minutes. Cells were lysed and Western blotting was performed 
with antibodies against p-Akt, p-ERK1/2, total AKT and total ERK. Hsc70 was used as 
a loading control. A representative of 2 experiments is shown. G. OPM2-EV-1 cells 
were treated with 1µM CCX9588 or 0.01% DMSO vehicle control for 24 hours and 
migrated towards 100ng/ml rhCCL3 or media alone. H. RPMI-8226-luc cells were 
treated with 100nM CCX9588 or 0.01% DMSO vehicle control for 24 hours and 
migrated towards 100ng/ml rhCCL3 or media alone. Graphs depict mean ± SEM of 
three or more independent experiments (A-D, G-H). **p<0.01, *p<0.05, one-way 
ANOVA with Tukey’s multiple comparisons test (C) two-way ANOVA with Sidak’s 
multiple comparisons test (G-H). 
 
 





























































































































































































































behaviour or physical appearance, or analysis of PB cell counts (Supplementary Table 2.1). 
Mean trough serum concentration of CCX9588 achieved in vivo was 328nM (range: 76.8-
886nM; Supplementary Figure 2.2B). 
In mice bearing OPM2-EV-1 or RPMI-8226-luc cells, primary tumour burden was 
unaffected by CCX9588 treatment compared with vehicle controls as assessed by flow 
cytometry (OPM2-EV-1: p=0.91, Figure 2.6A; RPMI-8226-luc: p=0.49, Figure 2.6B). 
Consistent with the effect of CCR1 knockout in OPM2 cells, we observed in vivo a 66% 
decrease in the mean number of circulating tumour cells in the OPM2-EV-1 model 
(p<0.0001; vehicle: 23.9 ± 3.12% of total parent population [mean ± SEM]; CCX9588: 
8.05 ± 1.72%; Figure 2.6C); while the decrease in circulating tumour cells in the RPMI-
8226-luc model did not reach statistical significance (p=0.09; vehicle: 0.233± 0.146% of 
total parent population [mean ± SEM]; CCX9588: 0.0662 ± 0.0210%; Figure 2.6D). 
CCX9588 treatment significantly reduced dissemination to the bone, with a 22% reduction 
in mean tumour burden in the contralateral limb in the OPM2-EV-1 model (vehicle: 78.1 ± 
2.12% of total parent population [mean ± SEM]; CCX9588: 60.8 ± 3.24%; p<0.001; 
Figure 2.6E) and a 70% reduction in mean tumour burden in the contralateral limb in the 
RPMI-8226-luc model (p<0.0001; vehicle: 0.855 ± 0.152% of total parent population 
[mean ± SEM]; CCX9588: 0.259 ± 0.0510%; Figure 2.6F) compared with controls. 
Furthermore, the degree of splenomegaly resulting from tumour infiltration in the OPM2-
EV-1 model was significantly reduced compared with vehicle controls in CCX9588-treated 
mice (p<0.001; non-tumour control: 1.10 ± 0.0413 cm in length [mean ± SEM]; vehicle: 
2.37 ± 0.0618 cm; CCX9588: 1.92± 0.0767 cm; Figure 2.6G). Splenomegaly was not 
observed in the RPMI-8226-luc model, precluding assessment of the effect of CCX9588 
on splenic dissemination (Figure 2.6G). When CCX9588 treatment was delayed until two 
weeks post OPM2-EV-1 tumour cell inoculation, CCX9588-treated mice showed 
significantly reduced numbers of circulating tumour cells (p<0.01; vehicle: 13.5 ± 2.50% 
of total parent population [mean ± SEM]; CCX9588: 4.73 ± 0.560%; Supplementary 
Figure 2.3B) although delayed treatment did not significantly decrease tumour burden in 




















































Figure 2.6. CCR1 inhibition reduces circulating MM PC numbers and tumor 
dissemination in NSG mice bearing OPM2 or RPMI-8226 cells. A. Primary tumor 
burden in injected tibiae after 4 weeks in NSG mice injected with OPM2-EV-1 cells 
and treated Days 3-28 with CCX9588 (15mg/kg) or vehicle control at 12-hour intervals. 
B. Primary tumor burden in injected tibiae after 4 weeks in NSG mice injected with 
RPMI-8226-luc cells and treated Days 3-28 with CCX9588 (15mg/kg) or vehicle 
control at 12-hour intervals. C. Number of circulating OPM2-EV-1 cells in peripheral 
blood of mice treated Days 3-28 with CCX9588 (15mg/kg) or vehicle control at 12-
hour intervals. D. Number of circulating RPMI-8226-luc cells in peripheral blood of 
mice treated Days 3-28 with CCX9588 (15mg/kg) or vehicle control at 12-hour 
intervals. E. Tumor burden disseminated to the non-injected contralateral leg in mice 
injected with OPM2-EV-1 cells treated Days 3-28 with CCX9588 (15mg/kg) or vehicle 
control at 12-hour intervals. F. Tumor burden disseminated to the non-injected 
contralateral leg in mice injected with RPMI-8226-luc cells treated Days 3-28 with 
CCX9588 (15mg/kg) or vehicle control at 12-hour intervals. G. Spleens collected from 
naïve NSG mice or vehicle- or CCX9558-treated mice bearing OPM2-EV-1 or RPMI-
8226-luc cells were measured to assess the degree of splenomegaly. Naïve mice splenic 
sizes are duplicated from Fig. 4D for comparison. Box and whisker plots depict median 
and interquartile range, n=10-12 mice/group (A,C,E), n=17 mice/group (B,D,F), n=7-
17 mice/group (G). **p<0.01, ***p<0.001, ****p<0.0001, Mann-Whitney test (C,E-



























































































































































































































































Symptomatic MM is characterised by the presence of multiple tumours throughout the 
skeleton, and in some patients, soft tissues. The dissemination of MM PCs is central to the 
progression of disease and subsequent disease relapse, highlighting the therapeutic 
potential of targeting of key factors that regulate dissemination to delay disease 
progression and prevent overt relapse. While the inhibition of several factors, including 
selectins,39 N-cadherin34,40 and CXCR441 have been demonstrated to slow BM homing of 
MM cells in vivo, very few genes have been demonstrated to play a role in the spontaneous 
dissemination of MM PCs from the BM in MM. For example, overexpression of 
heparanase, an enzyme that cleaves heparan sulfate chains, has been reported to increase 
the incidence of spontaneous dissemination of MM cells in a mouse MM xenograft 
model.42 Additionally, recent data suggests that the transcription factor Twist-1 increases 
dissemination in an intratibial 5TGM1/KaLwRij model in vivo.43 Furthermore, as far as we 
are aware, no therapeutic interventions have been described that can inhibit spontaneous 
dissemination of MM PCs in vivo. Here, our findings suggest a novel role for the 
chemokine receptor CCR1 in regulating the egress of MM PCs from the BM to the 
circulation during dissemination. These findings are consistent with a role for CCR1 in 
metastasis in other cancer settings, with a study showing that shRNA-knockdown of CCR1 
decreased migration of hepatocellular carcinoma cells in vitro and reduced the incidence of 
lung metastasis in vivo.44 
 
CCL3 is known to act as a potent chemoattractant for murine and human MM cell lines 
and patient-derived MM PCs in vivo.17,20,45 In accordance with these previous studies, we 
demonstrated that CCL3 acts as a chemoattractant for OPM2 and RPMI-8226 cells, which 
could be blocked with CCR1 KO or by treatment with the CCR1 inhibitor CCX9588. 
Furthermore, expression of CCR1 in the 5TGM1 murine cell line resulted in a chemotactic 
response to CCL3 that was not observed in EV controls, in vitro. While CCL3 has been 
shown to be produced by MSC20 and osteoclasts19,20 in the BM, the most abundant source 
of CCL3 in the BM in MM patients is suggested to be the MM PCs themselves.18-21 CCL3 
is abundantly expressed by MM cell lines and primary MM PCs18,19,24 and is present in 
high levels in the BM of MM patients.21,46 It is therefore likely that autocrine CCL3 
production would interfere with any chemoattractant effect of exogenous CCL3 in the MM 
BM and would not contribute significantly to the decreased dissemination with CCR1 
inhibition or KO observed here. Interestingly, we found that treatment of RPMI-8226-luc 
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CCL3. This is consistent with a previous study, whereby the CCR1 inhibitor BX471 
prevented basal migration of the human acute monocytic leukaemia cell line THP-1.47 This 
may suggest that autocrine CCL3 production in these cells may act to increase random 
non-directional migration (chemokinesis) in these cells, as has been described for 
chemokines CCL2 and IGF-1 in MM cell lines.48,49 Alternatively, CCR1 has been 
suggested to signal without the presence of ligand and induce agonist-independent 
migration of THP-1 cells and the murine pre-B lymphoma cell line L1.2.47 Decreased basal 
migration or chemokinesis of these cells in the presence of CCR1 inhibitor may, therefore, 
in part be responsible for the decrease in dissemination of RPMI-8226 cells observed in 
vivo.  
 
We have previously demonstrated that CCL3 treatment of HMCLs reduces their capacity 
to migrate towards exogenous CXCL12 or undergo cytoskeletal remodelling in response to 
CXCL12 treatment.17 Additionally, we demonstrated that migration towards CXCL12 of 
the human MM cell line U266, which produces abundant CCL3, could be restored 
following CCR1 knockout or treatment with a CCR1 inhibitor, strongly suggesting that 
CCL3/CCR1 signalling is responsible for blocking migration towards CXCL12 in these 
cells.17 Here, we demonstrate that CCR1 expression increases the capacity for 
dissemination, while CCR1 inhibition or KO decreases the formation of disseminated 
tumours in mouse models. We postulate that this is due to changes in CCR1 signalling 
interfering with CXCL12-mediated BM retention. We have previously shown that CCL3-
treatment of HMCLs results in a decreased chemotactic response to CXCL12 but no effect 
on CXCR4 cell-surface levels in vitro, suggesting that CCL3/CCR1 signalling can interfere 
with downstream CXCL12/CXCR4 signalling.17 In support of this, CCL3/CCR1 signalling 
drives mobilisation of haematopoietic progenitors and NK cells from the BM in part 
through inactivation of CXCR4.25,26,50 Our findings that CCR1 KO or inhibition 
significantly decreases the exit of MM PCs from the BM into the PB support our 
hypothesis that hypoxia-mediated upregulation of CCR1 may be critical for overcoming 
CXCL12-mediated BM retention and enabling mobilisation. 
 
We observed no effect of CCR1 expression or KO, in the presence or absence of 
exogenous CCL3, on the proliferation of MM cell lines in vitro. This was despite the 
ability of CCL3 to induce AKT and ERK phosphorylation, which are involved in known 
survival/proliferation pathways in MM.24 This contrasts with a previous study suggesting 
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that recombinant CCL3 increases HMCL proliferation in vitro.24 As such, the possibility 
that the relatively high serum concentration used in the current study could be providing 
sufficient other growth factors to mask the effects of CCL3 in vitro here cannot be 
excluded. We also saw no effect of CCX9588 treatment on the proliferation of OPM2 
cells, but a decrease in the proliferation of RPMI-8226 cells with 1µM CCX9588 
treatment. In contrast, a previous study has observed that treatment with the CCR1 
inhibitor CCX721 at high doses had no effect on the proliferation of RPMI-8226 cells in 
vitro,23 suggesting that the effects observed at high concentrations of CCX9588 here may 
be due to off-target effects. Importantly, CCR1 expression in the 5TGM1 cell line, or 
treatment with a CCR1 inhibitor in OPM2 and RPMI-8226 models did not affect primary 
tumour growth in vivo. Inhibition of CCL3 or CCR1 in the murine 5T2MM and 5TGM1 
models has previously been shown to decrease primary BM tumour growth, but not growth 
of subcutaneous tumours or cells in vitro.22,23  This suggests that CCL3/CCR1 inhibitors 
may effect growth factor production by cells of the BM microenvironment to indirectly 
affect 5TMM tumour growth.23 Similar effects were observed with osteoclast ablation 
using zoledronate, suggesting that these results may be secondary to decreased osteoclast 
activity/numbers in this model.23 The CCR1 inhibitor MLN3897 has previously been 
shown to decrease the pro-proliferative effects of osteoclast coculture on a CCR1-negative 
HMCL, at least in part through indirectly decreasing osteoclast IL6 secretion, supporting 
the idea that effects of CCR1 inhibition on tumour growth in some in vivo models may be 
due to secondary effects on osteoclasts.19 However, we found no effect of CCR1 inhibitor 
treatment on primary tumour growth in the RPMI-8226 or OPM2 xenograft model, 
suggesting that inhibition of microenvironmental CCR1 was not contributing to the effects 
we observed here. Notably, we have previously demonstrated that treatment with the 
CXCR4 inhibitor T140 had no effect on intratibial RPMI-8226 tumour growth, despite 
dramatic effects on osteolysis and decreased osteoclast numbers, suggesting that inhibition 
of osteoclasts does not affect primary tumour growth in this model.28 We did, however, 
observe in vivo that mice injected with OPM2-CCR1-KO cells had lower primary tumour 
burden compared with controls. As we did not observe an impact on primary tumour 
growth in any of the other mouse models, this suggests a potential clonal variance effect. 
Alternatively, there is a potential indirect effect, whereby an inability of the cells to leave 
the primary tumor site may be causing environmental pressures, such as an increase in 




Importantly, we are the first to assess the efficacy of the small molecule CCR1 inhibitor 
CCX9588 on dissemination in a pre-clinical model of MM. CCX9588 has been previously 
reported to decrease chemotaxis of T-cells towards liver conditioned media in vitro.52  
CCX9588 is an analogue of CCX354, which has previously been investigated as a 
therapeutic for rheumatoid arthritis in a clinical trial,53 and CCX721, which has been 
shown to have anti-osteolytic activity in an in vivo MM model.23 Initially we showed that 
CCX9588 can decrease CCL3-induced phosphorylation of AKT and ERK in a dose-
dependent manner in OPM2 cells. We also saw a similar dose-dependent reduction in AKT 
phosphorylation in RPMI-8226 cells, however under these conditions we did not observe 
an induction in ERK phosphorylation with CCL3 stimulation and therefore were not able 
to assess the effects of the inhibitor on p-ERK levels in these cells. Our in vivo studies have 
demonstrated that CCR1 inhibition can decrease dissemination of MM PCs in OPM2 and 
RPMI-8226 xenograft models. The OPM2 cell line was originally established from a 
patient with plasma cell leukemia,54 and produces a rapidly growing and highly 
disseminated disease model in NSG mice. In our study, treatment with the CCR1 inhibitor 
CCX9588 only had a relatively small effect on disseminated tumour burden in the 
contralateral leg, suggesting that residual disseminating cells during treatment are 
sufficient to populate the marrow at secondary sites. In contrast, RPMI-8226 cells, derived 
from a MM patient with no detectable circulating MM PCs on smear,55 produces a less 
aggressive model, with a more dramatic reduction in the formation of disseminated BM 
tumours with CCR1 inhibitor treatment in our study. While we were not able to completely 
prevent dissemination of MM PCs using CCX9588 at this dose, these studies suggest that 
impeding the egress of MM PCs from the BM to the circulation could slow the 
development of disease. Further studies are required to determine whether combination 
therapy with other anti-myeloma agents, or more intensive treatment regimens, could 
achieve an enhanced effect on tumour dissemination and subsequent outgrowth in these 
models. 
 
In summary, our studies have identified a novel role for the chemokine receptor CCR1 in 
the context of MM pathogenesis, demonstrating that CCR1 is a key driver of MM PCs 
egress from the BM to the circulation during dissemination. Furthermore, we have shown 
that inhibition of CCR1 via therapeutic targeting or KO can slow dissemination. Together 
with previous studies demonstrating that targeting of CCR1 prevents the development of 
severe osteolytic lesions in vivo, our study demonstrating that CCR1 regulates 
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dissemination presents CCR1 as an attractive therapeutic target for MM. Future preclinical 
studies are warranted to investigate whether therapeutic inhibition of CCR1 has efficacy as 
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Supplementary Figure 2.1. Verification of OPM2 CCR1 knockout cell lines. A. 
Schematic diagram of CRISPR-Cas9 strategy OPM2 to generate CCR1-KO-1 cell line. 
P1 and P2 represent forward and reverse sequencing primers, respectively, and location 
of gRNA-A and -B binding sites are indicated. B. PCR to confirm CRISPR-Cas9 
deletion of the CCR1 exon in OPM2-CCR1-KO-1 cells compared with non-deleted 
CCR1 sequence in OPM2-EV-1 cells. C. Sanger sequencing of OPM2-CCR1-KO-1 
deletion band. D. Schematic diagram of CRISPR-Cas9 strategy OPM2 to generate 
CCR1-KO-2 cell line. P1 and P2 represent forward and reverse sequencing primers, 
respectively, and location of gRNA-C binding site is indicated. E. CRISPR-Cas9 
mutagenesis of the CCR1 exon was confirmed by PCR and acrylamide gel 
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Supplementary Figure 2.2. Four-week treatment of NSG mice with twice daily 
treatment with the CCR1 inhibitor CCX9558 was well-tolerated in vivo. A. Trough 
serum concentrations of CCX9588 (Cmin) were measured 12 hours after the final dose 
in OPM2-tumor bearing CCX9588-treated NSG mice. B. Weights of OPM2-tumor 
bearing NSG mice were treated with PEG vehicle or CCX9588 via twice daily oral 
gavage daily for 25 days. Graph depicts median and interquartile range, n=10 mice (A), 
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Supplementary Table 2.1. Complete blood counts of OPM2-tumour bearing
NSG1 mice following 25-day CCX9588 treatment


















































Supplementary Figure 2.3. Targeting of CCR1 reduces circulating tumour cell 
numbers in NSG mice with established OPM2 tumour cells. Targeting of CCR1 
reduces circulating tumor cell numbers in NSG mice with established OPM2 
tumor cells. A. Primary tumor burden in injected tibiae after 4 weeks in NSG mice 
injected with OPM2-EV-1 cells and treated Days 14-28 with CCX9588 (15mg/kg) or 
vehicle control at 12-hour intervals. B. Number of circulating OPM2-EV-1 cells in 
peripheral blood of mice treated Days 14-28 with CCX9588 (15mg/kg) or vehicle 
control at 12-hour intervals, as assessed by flow cytometry. C. Number of circulating 
RPMI-8226-luc cells in peripheral blood of mice treated Days 14-28 with CCX9588 
(15mg/kg) or vehicle control at 12-hour intervals, as assessed by flow cytometry. D. 
Spleens collected from naïve NSG mice or vehicle- or CCX9558-treated mice bearing 
OPM2-EV-1 cells were measured to assess the degree of splenomegaly. Naïve mice 
splenic sizes are duplicated from Fig. 4D for comparison. Box and whisker plots 
depict median and interquartile ranges, n=9 mice/group (A-C), n=7-9 mice per group 
(D). **p<0.01, Mann-Whitney test (B), ****p<0.0001, ordinary one-way ANOVA 
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The introduction of the proteasome inhibitor, bortezomib, for the treatment of the 
haematological malignancy multiple myeloma (MM), has improved survival rates. 
However, a large proportion of patients exhibit resistance to bortezomib for which the 
mechanisms remain to be fully elucidated. We have previously shown that elevated CCR1 
expression in MM plasma cells (PCs) is associated with poor prognosis in newly diagnosed 
MM patients. Here, we hypothesise that the poor prognosis conferred by CCR1 expression 
is, in part, due to decreased MM PC sensitivity to bortezomib. Initially, we expressed 
CCR1 in the murine MM cell line 5TGM1 and found that CCR1 expression conferred a 
decreased sensitivity to bortezomib treatment in vitro. In addition, CRISPR-Cas9-mediated 
knockout of CCR1 in human OPM2 MM PCs rendered OPM2 cells significantly more 
sensitive to bortezomib treatment in vitro and in vivo. In contrast, we demonstrated that 
addition of recombinant CCL3 or siRNA-mediated knockdown of autocrine CCL3, did not 
affect response to bortezomib in vitro. CCR1 expression was shown to negatively regulate 
the expression of the unfolded protein response receptor IRE1, which may, in part, be 
responsible for the decreased sensitivity to bortezomib of CCR1 expressing cell lines. In 
support of this, CCR1 levels inversely correlated with IRE1 levels in primary BM MM 
PCs. Notably, CCR1 is expressed in over 60% of newly diagnosed MM patients, with 
elevated CCR1 expression at diagnosis, or induction of CCR1 expression in BM MM PCs 
at relapse being associated with poor prognosis in patients treated with bortezomib-based 
regimens. Taken together, these studies suggest that CCR1 expression decreases sensitivity 
of MM PCs to bortezomib therapy via a mechanism that may involve downregulation of 
IRE1. As bortezomib is commonly used in frontline and second-line therapeutic regimens 
in MM, future studies should investigate whether CCR1 inhibition could improve response 




Multiple myeloma (MM) is an incurable haematological malignancy characterised by the 
uncontrolled growth of clonal plasma cells (PC) within the bone marrow (BM).1 MM is 
preceded by the asymptomatic precursor disease monoclonal gammopathy of 
undetermined significance (MGUS), characterised by the presence of low numbers of 
clonal PC in the BM but no evidence of end organ damage that is typically associated with 
overt MM.1 In Europe,2 the USA3 and Australia,4 the proteasome inhibitor, bortezomib, is 
a common frontline treatment, used in approximately 50% of MM patients. Since its 
introduction, bortezomib has led to significant improvements in patient survival, with an 
increase in the relative five-year survival rate to almost 50%.5 However, resistance to 
bortezomib represents a major hurdle in the successful treatment of MM patients.6,7 For 
instance, approximately 20% of patients present with intrinsic therapeutic resistance and do 
not respond to frontline bortezomib-containing regimens.8 In addition, acquired resistance 
is common in patients treated with bortezomib, with approximately 40-50% of patients 
relapsing or becoming unresponsive to retreatment.9,10 Despite the clinical need, 
therapeutic strategies to overcome bortezomib resistance are lacking, highlighting the need 
to fully understand the mechanisms of bortezomib resistance in MM. 
 
Proteasome inhibitors, like bortezomib, exert broad anti-tumour effects, including causing 
the accumulation of misfolded proteins leading to activation of the unfolded protein 
response (UPR), and stabilisation of pro-apoptotic molecules which induce apoptosis.7,11 
Activation of the UPR is thought to be the mechanism by which bortezomib exerts it major 
anti-tumour effect as MM PCs undergo ER expansion to accommodate the synthesis of 
secreted immunoglobulin.12,13 Bortezomib binds to the active site of the 26S proteasome,14 
inducing ER stress through the accumulation of unfolded proteins and prevention of ER-
associated degradation. This, in turn, induces the UPR, which is activated when the 
accumulation of unfolded or misfolded proteins leads to the dissociation of the ER 
chaperone binding immunoglobulin protein (BiP, also known as heat shock protein family 
A (Hsp70) member 5 [HSPA5]) from the three UPR transmembrane stress sensors: 
inositol-requiring kinase 1 (IRE1, also known as endoplasmic reticulum to nucleus 
signalling 1 [ERN1]), protein kinase R-like ER kinase (PERK) and activating transcription 
factor 6 (ATF6). Importantly, IRE1, PERK and ATF6 signalling induce the expression of 
genes responsible for adaption to stress conditions;15,16 however, bortezomib induces 
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prolonged ER stress, leading to the induction of pro-apoptotic signalling pathways in, what 
is termed, the terminal UPR response.13,17  
 
The C-C motif chemokine receptor 1 (CCR1) is a G protein-coupled receptor whose most 
potent ligand is the C-C motif chemokine ligand 3 (CCL3; also known as macrophage 
inflammatory protein 1 alpha (MIP-1a)). CCL3 activation of CCR1 results in the 
activation of PI3K/AKT and MEK/ERK signalling pathways associated with cell 
survival.18 We have previously shown that elevated BM MM PC expression of CCR1 is 
associated with a poor prognosis in newly diagnosed MM patients  in the Total Therapy 2 
and 3 clinical trials which included bortezomib-based regimens.19 As shown in Chapter 2, 
CCR1 expression plays a pivotal role in MM PC dissemination in vivo, without affecting 
cell proliferation in vitro or in vivo. Notably, a previous study suggests that CCR1/CCL3 
signalling may play a role in bortezomib and chemotherapy resistance in transformed B-
cell lines,20 suggesting a potential mechanism which could account for the association 
between elevated CCR1 and poor prognosis in MM. We therefore hypothesised that the 
prognostic disadvantage of elevated CCR1 expression is due, in part, to increased MM PC 
resistance to bortezomib. In the studies presented here, we investigated whether CCR1 
overexpression or knockout affected survival of MM cell lines following bortezomib 
therapy in vitro and in vivo, and whether addition of CCL3 or endogenous CCL3/CCR1 
signalling influenced this response. In addition, we assessed the expression of CCR1 on 
BM MM PCs isolated from newly diagnosed MM patients using flow cytometry and 
examined the association between CCR1 expression and survival of MM patients treated 




3.3.1. Cell culture 
All cell culture reagents were sourced from Sigma-Aldrich (St Louis, MO) unless 
otherwise stated. All media were supplemented with 2mM L-glutamine, 100U/ml 
penicillin, 100μg/ml streptomycin, 1mM sodium pyruvate and 10mM HEPES. Human 
MM cell lines OPM2-EV-1, OPM2-CCR1-KO-1 (Chapter 2) and U266 were maintained in 
Roswell Park Memorial Institute 1640 (RPMI-1640) medium with 10% foetal calf serum 
(FCS; Thermo Fisher Scientific, Waltham, MA) and supplements. The mouse MM cell 
lines 5TGM1-EV and 5TGM1-CCR1 (Chapter 2) were maintained in Iscove’s modified 
Dulbecco’s medium (IMDM) with 20% FCS and supplements. All cell lines were routinely 
cultured in a humidified environment with 5% carbon dioxide at 37°C. Where indicated, 
cells were treated with recombinant human (rh) CCL3 (100 ng/mL; R&D Systems, 
Minneapolis, MN) and/or bortezomib (0-160nM; Selleck Chemicals, Houston, TX). 
 
3.3.2. In vitro bortezomib sensitivity assays 
WST-1 assays were conducted as previously described.21 For 5TGM1 cell lines, cells were 
plated at 1x105 cells/mL in triplicate in phenol red free IMDM medium containing 20% 
FCS and supplements. For OPM2 and U266 cell lines, cells were plated at 1x105 cells/mL 
in triplicate in phenol red free RPMI-1640 medium containing 10% FCS and supplements. 
Where indicated, cells were seeded in media containing bortezomib (0-160nM, all 
containing 0.002% DMSO) with, or without, rhCCL3 (100 ng/mL). After 24 hours, WST-1 
reagent (Roche, Basel, Switzerland) was added and cells incubated at 37°C as per 
manufacturer’s instructions and absorbance was read on an iMark™ Microplate 
Absorbance Reader at 450nM (BioRad) to quantitate relative numbers of viable cells per 
well. 
 
3.3.3. siRNA-mediated knockdown of CCL3 
All reagents were sourced from Thermo Fisher Scientific, unless otherwise specified. 
Silencer Select Negative Control No. 1 siRNA (Cat. 4390843) and pre-designed CCL3- 
targeting siRNAs (Assay ID s12568, siRNA#1; Assay ID s199846, siRNA#2) were pre-
incubated in Opti-MEM at 150nM with 15μl/mL Lipofectamine RNAiMAX reagent for 15 
minutes at room temperature. U266 or OPM2 cells were washed and resuspended in Opti-
minimal essential medium (MEM) at 2.5x105 cells/mL and siRNA-lipid complexes were 
then added dropwise, for a final concentration of 25nM siRNA and 2.5μL/mL 
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Lipofectamine RNAiMAX reagent, and flasks were gently rocked to mix. After 6 hours at 
37°C, cells were diluted 2-fold with antibiotic-free RPMI-1640 containing 10% FCS and 
supplements and cultured for 2 (OPM2) or 3 (U266) days. At day 2 or 3, cells were 
harvested for RNA isolation using TRIzol reagent. 
 
3.3.4. Real time quantitative PCR (qPCR) 
Total RNA was isolated using TRIzol reagent (Thermo Fisher Scientific) and DNase 
treated using RQ1 DNase as per manufacturer’s instructions (Promega, Madison, WI). 
Complementary DNA (cDNA) was synthesized using Superscript IV First-Strand 
Synthesis System (Thermo Fisher Scientific). qPCR was performed using a CFX Connect 
9000 Real-Time PCR machine (BioRad). Sequences for human and mouse primers are 
outlined in Supplementary Table 3.1. Changes in gene expression were calculated relative 
to ACTB/ActB using the 2-DDCt method.22 
 
3.3.5. Western blotting 
MM cell lines were treated with bortezomib (5-20nM) or vehicle (0.002% DMSO) for 6 
hours in RPMI-1640 medium containing 10% FCS and supplements (OPM2-EV-1 and 
OPM2-CCR1-KO-1) or IMDM medium containing 20% FCS and supplements (5TGM1-
EV and 5TGM1-CCR1). Cells were washed once in phosphate buffered saline (PBS) and 
cell lysates were prepared as previously described.23 Proteins (50µg) were resolved under 
reducing conditions on 10% SDS-PAGE gels and transferred to 0.45µm nitrocellulose 
membranes. Immunoblotting was performed with the following antibodies: phosphorylated 
JNK and total IRE1α (Cell Signaling Technologies, Danvers, MA, USA; both at 1:1000) 
and α-tubulin as a loading control (Abcam, Cambridge, UK; 1:5000). Membranes were 
developed using Dylight™-680 or 800 conjugated secondary antibodies (Invitrogen, 
Carlsbad, CA; 1:20,000) and visualised using the Odyssey Infrared Imaging system (LI-
COR Bioscience, Lincoln, NE, USA). 
 
3.3.6. NOD-scid gamma (NSG) murine model of myeloma 
NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG)24 mice were bred and housed at the SAHMRI 
Bioresources facility. All animal studies were approved by and performed in accordance 
with the SAHMRI Animal Ethics Committee (ID #286). Female NSG mice (5-6 weeks 
old) were inoculated with 5x105 OPM2-EV-1 or OPM2-CCR1-KO-1 cells in 10µl PBS via 
intratibial injection. Mice were administered bortezomib (0.7mg/kg) or 0.03% DMSO 
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control diluted in PBS intravenously on days 7, 11, 14, 18, 21 and 25 post tumour cell 
injection. On day 28, mice were humanely euthanised and tumour cell-injected tibiae were 
isolated. Tibiae were flushed with 10mL PBS containing 2% FCS and 2mM EDTA (PFE), 
centrifuged for 10mins at 1400rpm and resuspended in 1mL PFE prior to analysis of GFP-
positive tumour cells by flow cytometry using a LSRFortessa flow cytometer (BD 
Biosciences).  
 
3.3.7. Patient samples 
Ethical approval for this study was obtained from the University of Freiburg Medical 
Centre Ethics Review Committee and all patients provided written, informed consent, in 
accordance with the Declaration of Helsinki. Posterior superior iliac spine BM aspirates 
were collected at initial diagnosis from 28 MM patients that had not received prior therapy 
[median age: 68 years (range: 49–84); male:female ratio 1.15:1] and 8 patients with 
MGUS1 [median age: 74 years (range: 53-88); male:female ratio 1.7:1]. All MM patients 
fulfilled the diagnostic criteria for active MM disease.1 The patients presented at the 
Freiburg Universitätsklinikum between 15th June 2007 and 30th April 2019 (Freiburg, 
Germany). BM was collected in potassium EDTA tubes and mononuclear cells (BMMNC) 
were isolated by density gradient centrifugation (Ficoll) and were cryopreserved prior to 
use as described previously.25  
 
3.3.8. Flow cytometry 
Cell surface CCR1 expression was assessed on viable CD38++/CD138+/-/CD45lo/CD19- 
malignant PC in MM and MGUS patients by multicolour flow cytometry (FACSARIA III; 
BD Biosciences, San Jose, CA) as previously described.19 Briefly, 3x105 mononuclear 
cells per test were stained with either an anti-CCR1-PE (clone 53504; R&D systems, 
Minneapolis, MN) or no PE-conjugated primary antibody [fluorescence minus one (FMO) 
control], in combination with CD38-PE-Cy7 (clone HIT2; BioLegend, San Diego, CA), 
CD138-AlexaFluor-647 (clone B-A38; BioRad, Hercules, CA), CD45-FITC (clone J.33; 
Beckman Coulter, Brea, CA), and CD19-Brilliant Violet 421 (clone HIB19; BioLegend) 
antibodies. Cells were stained with the viability dye hydroxystilbamidine (FluoroGold; 
Invitrogen Life Technologies, Carlsbad, CA) immediately before analysis. Viable, single 
cells were gated on the basis of FSC and SSC characteristics and FluoroGold negativity 
and malignant PC were identified as CD38-bright cells. As CD138 was often lost upon 
freezing, CD138 positivity was not required for identification of the MM PC population. 
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Contaminating cells were subsequently excluded by gating on the CD45-low and CD19-
negative population. A minimum of 100 cells was required to fulfil these criteria to be 
identified as a malignant PC population. A minimum of 5x104 total nucleated cells were 
analysed per test, with a minimum of 1x105 cells analysed per patient. CCR1 expression 
was quantitated as the change in the median fluorescence intensity (DMFI), defined as the 
difference in MFI between the CCR1-stained sample and the FMO control. CCR1 
positivity was defined, based on the lowest detectable signal, as above DMFI of 83.  
 
3.3.9. Patient RNA-sequencing analysis 
RNA-sequencing data was obtained from the Multiple Myeloma Research Foundation 
(MMRF) CoMMpass (MMRF-COMMPASS) dataset, accessed via the NIH NCI GDC 
Data Portal (9 August 2019). Gene expression data (FPKM) for CD138-selected BM PC 
was included from all MM patients (n=43) who had RNA-sequencing performed from a 
sample taken at diagnosis (initial) and a sample taken following at least one line of therapy 
which included bortezomib (subsequent). Patients were categorised as having low tumour 
expression of CCR1 (CCR1 < 10 FPKM at both initial and subsequent biopsy; n=26; 
median age: 70 years [37-83]; male:female ratio 1.36:1), high CCR1 (CCR1 ≥ 10 FPKM at 
initial biopsy; n=7; median age: 66 years [39-70]; male:female ratio 1.31:1) or increased 
CCR1 (initial CCR1 < 10 FPKM and subsequent CCR1 ≥ 10 FPKM; n=10; median age: 66 
years [50-82]; male:female ratio 2.33:1). Median time between initial and subsequent 
samples was 490.5 days [range: 59-1419 days]. Overall survival was reported as death 
from any cause. 
 
3.3.10. Statistical Analyses 
Statistical analyses were performed using GraphPad Prism 7 (GraphPad Software Inc., San 
Diego, CA, USA). In vitro assays were analysed using an unpaired t-test for comparison 
between two cell lines, one-way ANOVA with Tukey’s multiple comparisons test for 
analysis of CCL3 gene expression, two-way ANOVA with Sidak’s multiple comparison’s 
test for time-course assays or two-way ANOVA with Tukey’s multiple comparisons test 
for bortezomib dose response assays. In vivo experiment was analysed using a two-way 
ANOVA with Sidak’s multiple comparisons test. For analysis of CCR1 expression on BM 
MM PCs a Mann-Whitney test was used. Overall survival was assessed using Kaplan-
Meier curves; comparisons between groups were made using the log-rank (Mantel-Cox) 
test and the Mantel-Haenszel hazard ratio. Correlation was assessed using Spearman 
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correlation co-efficient. Differences were considered statistically significant when the p 




3.4.1. Expression of CCR1 decreases sensitivity of MM cell lines to bortezomib in vitro 
and in vivo 
We have previously shown that elevated CCR1 expression in CD138-selected BM PC is 
associated with poor prognosis in newly diagnosed MM patients.19 Here, we hypothesised 
that the prognostic disadvantage of elevated CCR1 expression is, in part, due to decreased 
sensitivity to the proteasome inhibitor, bortezomib. Initially, we assessed the effects of 
bortezomib on CCR1-knockout OPM2-CCR1-KO-1 cells and control CCR1-expressing 
OPM2-EV-1 cells. There was a significantly higher reduction in cell number of OPM2-
CCR1-KO-1 cells compared with OPM2-EV-1 cells when treated with 10nM, 20nM and 
40nM bortezomib in vitro (OPM2-EV-1 IC50: 19.1nM, CCR1-KO-1 IC50: 8.1nM, p<0.01, 
Figure 3.1A). In addition, response to bortezomib treatment was investigated in CCR1-
expressing 5TGM1-CCR1 cells and CCR1-negative 5TGM1-EV controls. We observed a 
significantly lower reduction in cell number of 5TGM1-CCR1 cells compared with 
5TGM1-EV cells when treated with 6.25nM bortezomib or more in vitro (5TGM1-EV 
IC50: 7.2nM, 5TGM1-CCR1 IC50: 14.5nM, p<0.0001, Figure 3.1B).  
 
Next, we assessed the effect of CCR1 expression on the sensitivity of OPM2 cells to 
bortezomib in vivo using an intratibial orthotopic xenograft MM model. As reported in 
Chapter 2, we observed a significant reduction in tumour burden in NSG mice injected 
with OPM2-CCR1-KO-1 cells compared with OPM2-EV-1 cells in the saline-treated 
control groups (p<0.05, Figure 3.1C). Notably, OPM2-CCR1-KO-1 tumours were 
significantly more sensitive to bortezomib therapy than OPM2-EV-1 tumours (p<0.05, 
Figure 3.1C). In mice inoculated with OPM2-EV-1 control cells, bortezomib treatment 
resulted in a 41.0% reduction in mean primary tumour burden, compared with saline-
treated controls (saline: 97.3 ± 1.12 [mean ± SEM], bortezomib: 57.6 ± 15.0, Figure 3.1C). 
Notably, in mice injected with OPM2-CCR1-KO-1 cells, there was a 99.9% reduction in 
mean primary tumour burden following bortezomib treatment compared with saline 
controls (saline: 34.1 ± 18.8 [mean ± SEM], bortezomib: 0.250 ± 0.0290, Figure 3.1C).  
 
3.4.2. Decreased sensitivity of MM cell lines to bortezomib conferred by CCR1 is 





































Figure 3.1. Expression of CCR1 confers resistance to bortezomib in MM cell lines 
in vitro and in vivo. A. Relative number of OPM2 CRISPR-Cas9 CCR1 knockout 
(OPM2-CCR1-KO-1) or empty vector (OPM2-EV-1) control cells treated with 
bortezomib (0-80nM) for 24 hours as assessed by WST-1. B. Relative number of 
5TGM1 cells expressing CCR1 (5TGM1-CCR1) or 5TGM1-EV controls treated with 
bortezomib (0-40nM) for 24 hours as assessed by WST-1. C.  Primary tumour burden 
of OPM2-EV-1 or OPM2-CCR1-KO-1 inoculated NSG mice treated with bortezomib 
(0.7mg/kg) or saline vehicle control (0.33% DMSO) intravenously on days 7, 11, 14, 
18, 21 and 25 post-tumour cell injection. D. OPM2-CCR1-KO-1 or OPM2-EV-1 cells 
were treated with either bortezomib (10nM) with, or without, the addition of 
recombinant human rhCCL3 (100ng/mL), or with saline control (0.001% DMSO) 
with, or without, the addition of rhCCL3 for 24 hours and relative cell numbers were 
assessed by WST-1.  E. 5TGM1-CCR1 or 5TGM1-EV cells were treated with either 
bortezomib (7.5nM) with, or without, the addition of recombinant human rhCCL3 
(100ng/mL), or with saline control (0.001% DMSO) with, or without, the addition of 
rhCCL3 for 24 hours and relative cell numbers were assessed by WST-1.  Graphs 
depict mean ± SEM for two (D,E) or four to six (A,B) independent experiments. n=4-
5 mice/group (C). *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001, two-way ANOVA 



























5TGM1-EV IC50 = 7.2nM 





























OPM2-EV-1 IC50 = 19.1nM 







































































































































CCL3 is the most potent CCR1 ligand, and we have previously shown that CCL3 activates 
CCR1 signalling (Chapter 2). Previous studies have shown that treatment with a CCL3-
neutralising antibody increased the cytotoxic effect of bortezomib in a human immortalised 
B-cell line in vitro.20 To determine the role of CCL3 in CCR1-mediated resistance of MM 
PC to bortezomib, we initially assessed the effects of exogenous CCL3 on sensitivity to 
bortezomib in vitro. Consistent with our previous findings (Chapter 2), the addition of 
rhCCL3 had no effect on the basal proliferation of OPM2 (OPM2-EV-1: p>0.99, OPM2-
CCR1-KO-1: p>0.99, Figure 3.1D) or 5TGM1 (5TGM1-EV: p=0.31, 5TGM1-CCR1: 
p=0.97, Figure 3.1E) cells. Notably, while we observed that bortezomib significantly 
reduced OPM2-CCR1-KO-1 and 5TGM1-CCR1 and 5TGM1-EV cell numbers compared 
with untreated controls (p<0.05, Figure 3.1D, E), the addition of rhCCL3 showed no effect 
on the sensitivity of OPM2 (OPM2-EV-1: p=0.87, OPM2-CCR1-KO-1: p=0.76, 10nM 
bortezomib, Figure 3.1D) or 5TGM1 (5TGM1-EV: p>0.99, 5TGM1-CCR1: p>0.99, 
7.5nM bortezomib, Figure 3.1E) cells to bortezomib treatment. 
 
As we did not observe that exogenous CCL3 influenced the sensitivity of MM cell lines to 
bortezomib treatment, we hypothesised that endogenous production of CCL3 could be 
responsible for the differential response to bortezomib treatment mediated by CCR1. To 
investigate this, we knocked down CCL3 expression using siRNA in OPM2 cells (which 
endogenously expresses low amounts of CCL3), and in the human myeloma cell line U266 
(which endogenously expresses abundant CCL3).19 Initially, qPCR was conducted to 
confirm the timepoint required for optimal (>50%) knockdown for CCL3 in each cell line 
compared with negative control (NC) siRNA (OPM2 siRNA #1: 68% decrease, p<0.05; 
OPM2 siRNA #2: 86% decrease, p<0.01; U266 siRNA #1: 51% decrease, p < 0.05; U266 
siRNA #2: 54% decrease, p < 0.05; Figure 3.2A,B). Based on these analyses, bortezomib 
treatment was conducted following 48 hours of siRNA treatment for OPM2 cells and 72 
hours for U266 cells. When the cells were subsequently treated with bortezomib for 24 
hours, CCL3 knockdown in OPM2 and U266 cells was found to have no effect on their 
sensitivity to bortezomib treatment in vitro compared with their respective NC siRNA 
controls (OPM2: p=0.98, Figure 3.2C; U266: p=0.97, Figure 3.2D). Taken together, these 
studies demonstrate that neither exogenous nor endogenous CCL3 modulated the response 
of MM cell lines to bortezomib in vitro. 
 





















Figure 3.2. Increased resistance to bortezomib conferred by CCR1 expression is 
independent of CCL3/CCR1 signalling. A. CCL3 expression 48 hours following 
transfection of OPM2 cells with CCL3-targeting siRNA (siRNA #1 and siRNA #2) 
(normalised to negative control (NC) siRNA). B. CCL3 expression 48 hours following 
transfection of U266 cells with CCL3-targeting siRNA (siRNA #1 and siRNA #2) 
(normalised to negative control (NC) siRNA expression). C. OPM2 cells were treated 
with bortezomib (5-20nM) for 24 hours following transfection with NC or CCL3-
targeting siRNA (siRNA #1 and #2) and relative cell numbers were assessed by WST-
1. D. U266 cells were treated with bortezomib (2.5-10nM) for 24 hours following 
transfection with NC or CCL3-targeting siRNA (siRNA #1 and #2) and relative cell 
numbers were assessed by WST-1. Graphs depict mean ± SEM for two (A, C) or three 
(B, D) independent experiments. Data normalised to ACTB control (A,B). *p<0.05, 
**p<0.01, ***p<0.001, ****p<0.0001, one-way ANOVA with Tukey’s multiple 
comparisons test (A, B), two-way ANOVA with Tukey’s multiple comparisons test (C, 
D). 

















































































































































Previous studies have shown decreased expression of genes that trigger the ER stress 
response pathways to be associated with resistance to bortezomib.12,26-28 As such, we 
postulated that elevated CCR1 expression could affect bortezomib sensitivity of MM cells 
by modulating response to ER stress and subsequent induction of the UPR. Initially we 
assessed the basal gene expression of downstream targets of the UPR receptors IRE1, 
PERK and ATF6. The downstream effector of the PERK signalling pathway, ATF4, was 
not differentially expressed in OPM2-CCR1-KO-1 (ATF4: p=0.446, Figure 3.3A) or 
5TGM1-CCR1 (Atf4: p=0.573, Figure 3.3B) cells compared with respective EV controls. 
Similarly, the ATF6 signalling pathway target gene HSPA5 (gene for BiP) was not 
differentially expressed in OPM2-CCR1-KO-1 (HSPA5: p=0.385, Figure 3.3C) or 
5TGM1-CCR1 (Hspa5: p=0.966, Figure 3.3D) cells compared with respective EV 
controls. However, we found that the IRE1 downstream effector gene DnaJ heat shock 
protein family member C3 (DNAJC3; also known as protein kinase inhibitor p58 
(p58IPK)) was significantly increased in OPM2-CCR1-KO-1 cells compared with OPM2-
EV-1 cells (p<0.05, Figure 3.3E). However, there was no change in Dnajc3 expression in 
5TGM1-CCR1 cells compared with controls (p=0.924, Figure 3.3F).  
 
As expression of the IRE1 target gene DNAJC3 was increased in CCR1 knockout cells, we 
further investigated this UPR pathway in our CCR1-modified cell lines. ER stress is known 
to activate the IRE1 endonuclease which, in turn, splices the X-box binding protein 1 
(XBP1) mRNA into its active form, XBP1s. XBP1s then functions as a transcription factor 
which activates expression of genes responsible for protein folding and homeostasis, 
including DNAJC3.29 Basal levels of ERN1 (the gene encoding IRE1), total (spliced and 
unspliced forms) XBP1 and XBP1s mRNA were significantly increased in OPM2-CCR1-
KO-1 cells compared with OPM2-EV-1 cells (ERN1: p<0.05, Figure 3.4A; XBP1 total: 
p<0.01, Figure 3.4B; XBP1s: p<0.05, Figure 3.4C). Furthermore, CCR1-expressing 
5TGM1 cells basally expressed lower levels of Ern1, total Xbp1 and Xbp1s compared with 
5TGM1-EV controls (Ern1: p<0.05, Figure 3.4D; Xbp1 total: p<0.05, Figure 3.4E; Xbp1s: 
p<0.05, Figure 3.4F), further suggesting that CCR1 may negatively regulate this pathway. 
 
We then investigated IRE1 pathway signalling in the response to bortezomib in our CCR1 
modified MM cell lines (Figure 3.5). In line with the increase in basal ERN1 expression 












































Figure 3.3. CCR1 expression negatively regulates a target gene downstream of the 
IRE1 pathway but not genes downstream of the PERK and ATF6 pathways. A. 
Basal PERK target gene ATF4 expression in OPM2-CCR1-KO-1 or OPM2-EV-1 
control cells as assessed by qPCR. B. Basal PERK target gene Atf4 expression in 
5TGM1-CCR1 or 5TGM1-EV control cells as assessed by qPCR. C. Basal ATF6 target 
gene HSPA5 expression in OPM2-CCR1-KO-1 or OPM2-EV-1 control cells as assessed 
by qPCR. D. Basal ATF6 target gene Hspa5 expression in 5TGM1-CCR1 or 5TGM1-
EV control cells as assessed by qPCR. E. Basal IRE1 target gene DNAJC3 expression 
in OPM2-CCR1-KO-1 or OPM2-EV-1 control cells as assessed by qPCR. F. Basal IRE1 
target gene Dnajc3 expression in 5TGM1-CCR1 or 5TGM1-EV control cells as 
assessed by qPCR. Graphs depict mean ± SEM of 4 or more independent experiments 



























































































































































































































Figure 3.4. CCR1 expression negatively regulates expression of IRE1 and its 
pathway. A. Basal ERN1 (gene for IRE1) expression, as assessed by qPCR, in OPM2-
EV-1 or OPM2-CCR1-KO-1 cells. B. Basal XBP1 total (spliced and unspliced forms) 
expression, as assessed by qPCR, in OPM2-EV-1 or OPM2-CCR1-KO-1 cells. C. Basal 
XBP1 spliced expression, as assessed by qPCR, in OPM2-EV-1 or OPM2-CCR1-KO-1 
cells. D. Basal Ern1 expression, as assessed by qPCR, in 5TGM1-EV or 5TGM1-CCR1 
cells. E. Basal Xbp1 total (spliced and unspliced forms) expression, as assessed by 
qPCR, in 5TGM1-EV or 5TGM1-CCR1 cells. F. Basal Xbp1 spliced expression, as 
assessed by qPCR, in 5TGM1-EV or 5TGM1-CCR1 cells. Graphs depict mean ± SEM 
of 4 or more independent experiments normalised to ACTB/ActB controls. *p<0.05, 









































































































































































































































Figure 3.5. CCR1 expression decreases IRE1 protein expression both basally and 
following bortezomib treatment in MM cell lines. A. OPM2-EV-1 and OPM2-CCR1-
KO-1 cells were exposed to increasing concentrations of bortezomib for 6 hours and 
examined by Western blot for IRE1α and p-JNK proteins. Tubulin was used as a loading 
control. qPCR analysis for CHOP was performed in parallel and graph depicts one 
representative of three independent experiments. B. 5TGM1-EV and 5TGM1-CCR1 
cells were exposed to increasing concentrations of bortezomib for 6 hours and examined 
by Western blot for IRE1α and p-JNK proteins. Tubulin was used as a loading control. 
qPCR analysis for CHOP was performed in parallel and graph depicts one 
representative of four independent experiments normalised to ActB control. C. 
Schematic diagram of how CCR1 expression regulates IRE1 expression and subsequent 
pro-apoptotic signalling to confer changes in bortezomib sensitivity. Western blot 
depicts one of three independent experiments (A, B). ****p<0.0001, two-way ANOVA 










































































expression in OPM2-CCR1-KO-1 compared with EV cells, as assessed by Western 
blotting (Figure 3.5A). In line with this, we also found a decrease in basal Ire1 protein 
expression in 5TGM1-CCR1 compared with EV cells, as shown by Western blotting 
(Figure 3.5B). Furthermore, treatment with 20nM bortezomib for 6 hours led to an 
induction in IRE1 protein expression in OPM2-EV-1 cells, but no induction was observed 
in OPM2-CCR1-KO-1 cells due to the high basal expression levels. In addition, induction 
of Ire1 protein was not detectable in 5TGM1 cell lines at the bortezomib concentrations 
used here.  
 
Under sustained ER stress, a terminal UPR response leads to increased expression of the 
pro-apoptotic transcription factor CCAAT/enhancer binding protein homologous protein 
(CHOP).13 In addition, IRE1 also activates a cell death pathway via phosphorylation of the 
stress kinase, c-Jun N-terminal kinase (JNK), leading to activation of caspase-dependent 
apoptosis.17 To this end, we assessed levels of CHOP and phosphorylated JNK (p-JNK) in 
our CCR1-modified cell lines in response to bortezomib. Bortezomib treatment led to a 
dose-dependent induction of p-JNK and CHOP mRNA in OPM2-EV-1 and OPM2-CCR1-
KO-1; however, neither basal nor bortezomib-induced p-JNK or CHOP levels were 
significantly different between the cell lines (Figure 3.5A). In contrast, while bortezomib 
induced a dose-dependent increase in p-JNK and CHOP in both 5TGM1-CCR1 and 
5TGM1-EV cells, the magnitude of the increase in p-JNK and CHOP in response to 
bortezomib treatment was lower in 5TGM1-CCR1 cells compared with EV controls 
(Figure 5B). Taken together, these data suggest that CCR1 expression negatively regulates 
IRE1 expression in OPM2 and 5TGM1 cell lines. Furthermore, in 5TGM1 cells, this leads 
to reduced induction of p-JNK and CHOP expression in response to bortezomib treatment, 
consistent with a decreased induction of apoptosis pathways in these cells (Figure 3.5C).  
 
3.4.4. Elevated CCR1 expression at diagnosis, or induction of CCR1 expression at 
relapse, is associated with poorer prognosis in MM patients 
Using in silico analysis, we have previously shown that CCR1 expression in BM MM PCs 
is elevated in approximately 70% of newly diagnosed MM patients compared with BM 
PCs from healthy individuals.19 Furthermore, we showed that 81% (13/16) of newly 
diagnosed MM patients express detectable CCR1 on BM MM PCs by flow cytometry.19 
Here, we used multi-colour flow cytometry to examine CCR1 expression on 
CD38++/CD138+/-/CD45lo/CD19- BM MM PCs in a cohort of 28 newly diagnosed MM and 
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8 MGUS patients. In accordance with our previous study, we found that the majority, 
64.3% (18/28), of MM expressed detectable CCR1 (Figure 3.6A). Furthermore, CCR1 
protein expression was detectable in 25% (2/8) of MGUS patients (Figure 3.6A), and was 
found to be significantly higher in BM PC from MM patients (DMFI median: 108, range: -
36-1598) than those from MGUS patients (DMFI median: 8.60, range: -36-295; p<0.05, 
Figure 3.6A), consistent with our previous microarray analysis.19  
 
To investigate whether CCR1 expression is associated with disease response to bortezomib 
therapy in MM patients, we used RNA-sequencing analysis of CCR1 expression in 
CD138-selected BM MM PCs isolated from a cohort of MM patients collected as part of 
the CoMMpass study. In this cohort, BM samples were taken at diagnosis (initial) and 
following at least one line of therapy which included bortezomib at relapse (subsequent). 
We observed that 16.3% (n=7/43) of patients had high (≥ 10 FPKM) CCR1 expression at 
baseline. In the patients with low (< 10 FPKM) CCR1 expression at baseline, 72.2% 
(n=26/36) patients maintained low CCR1 expression both at initial and subsequent 
samples. In contrast, in 27.8% (n=10/36) of patients which displayed low initial CCR1 
expression, showed elevated (≥ 10 FPKM) CCR1 expression in the subsequent sample 
post-therapy (Figure 3.6B). Importantly, high CCR1 BM MM PC expression at diagnosis 
was significantly associated with poor prognosis, compared with patients in the low CCR1 
group (p<0.05, hazard ratio=4.3 [95% CI: 1.03-18.1], Figure 3.6C). Furthermore, there was 
a trend towards induction of CCR1 expression post-therapy also being associated with poor 
prognosis (p=0.080, hazard ratio=3.0 [95% CI: 0.88-10.44], Figure 3.6C). Notably, MM 
PC expression of CCR1 was found to be inversely correlated with ERN1 (IRE1) expression 
in MM patients following therapy (r=-0.24, p=0.026, Figure 3.6D), consistent with the 









































Figure 3.6. Elevated CCR1 expression at diagnosis, or induction of CCR1 
expression at relapse is associated with poorer prognosis in MM patients. A. 
Multicolour FACS analysis was performed to assess the expression of CCR1 on 
CD38++/CD138+/-/CD45lo/CD19- BM MM patient plasma cells. Plots of anti-CCR1-
PE-stained cells (open histogram) and fluorescence minus one (FMO) controls (filled 
histogram) are shown for four representative patients (P1–P4). CCR1 expression 
(DMFI) is shown for CD38++/CD138+/-/CD45lo/CD19- BM MM PC isolated from 8 
MGUS and 28 newly diagnosed MM patients. B. Gene expression data (FPKM) for 
CD138-selected BM MM PC for patients with a sample taken at diagnosis (initial) and 
a sample taken following at least one line of therapy with bortezomib (subsequent) 
(CoMMpass dataset, n=43). Patients were categorised as having low tumour 
expression of CCR1 (CCR1 < 10 FPKM at both initial and subsequent biopsy; n=26), 
high CCR1 (CCR1 ≥ 10 FPKM at initial biopsy; n=7) or increased CCR1 (initial CCR1 
< 10 FPKM and subsequent CCR1 ≥ 10 FPKM; n=10). C. Kaplan-Meier plots of 
overall survival are shown for MM patients stratified based on low CD138-selected 
BM MM PC expression of CCR1 (CCR1 < 10 FPKM at both initial and subsequent 
biopsy; n=26), high CCR1 (CCR1 ≥ 10 FPKM at initial biopsy; n=7) or increased 
CCR1 (initial CCR1 < 10 FPKM and subsequent CCR1 ≥ 10 FPKM; n=10) 
(CoMMpass dataset, n=43). D. CCR1 expression plotted against ERN1 (gene for 
IRE1) expression in CD138-selected BM MM PC isolated from MM patients at a 
sample taken at diagnosis (initial) or at a sample taken following at least one line of 
therapy with bortezomib (subsequent) (CoMMpass dataset, n=43). r and p values are 
shown for Spearman correlation analysis (D). Box plot depicts median with 

















































































































While the introduction of the proteasome inhibitor bortezomib has greatly improved the 
survival of MM patients, intrinsic or acquired resistance to bortezomib is commonly 
observed in MM patients, leading to poor initial response to therapy or relapse.6,7 As 
bortezomib is commonly used as the backbone to therapeutic regimens,2-4 resistance to 
bortezomib poses a challenge for the successful treatment of MM patients. However, the 
mechanisms of resistance remain poorly understood, and it is crucial to identify these 
mechanisms in order to overcome resistance. 
 
Chemokine receptors have been shown to play a role in chemotherapeutic resistance in 
multiple cancer types. For example, the interleukin 8 receptor, CXCR2, has been 
implicated in drug resistance in prostate and breast cancer cell lines, with shRNA 
knockdown or pharmaceutical inhibition significantly increasing the cytotoxicity of 
chemotherapeutics.30,31 Additionally, inhibition of CXCR4 increased the sensitivity of 
leukaemic32 and pancreatic cancer cell lines to therapy in vitro.33 Elevated expression of 
CXCR4 was also associated with lower chemosensitivity in epithelial ovarian cancer 
patients.34 Furthermore, addition of the chemokine CCL25, the ligand for CCR9, has been 
shown to reduced therapy-induced cell death of ovarian cancer cell lines.35 Using 
microarray analysis, we previously showed that CCR1 is expressed in approximately 70% 
of newly diagnosed MM patients, and elevated BM MM PC expression of CCR1 is 
associated with poor prognosis in newly diagnosed patients treated with bortezomib-based 
regimens.19 Here, we report for the first time, a role for CCR1 in mediating the resistance 
of MM PCs to bortezomib treatment. Using CCR1-expression or CCR1-knockout in 
murine and human MM cell lines in vitro, we showed that CCR1-expression decreased 
sensitivity, while CCR1-knockout increased sensitivity to bortezomib. In support of this, 
CCR1 has been shown to play a role in the resistance of prostate cancer cells to 
therapeutics, with a taxane-resistant PC3 prostate cancer cell line expressing CCR1 at high 
levels compared with taxane-sensitive controls in vitro.36 Furthermore, analysis of publicly 
available RNA-sequencing data from BM MM PCs isolated from MM patients prior to 
therapy and at relapse supported our in vitro findings that CCR1 increases MM PC 
bortezomib resistance, demonstrating that elevated CCR1 expression pre-treatment, or 
induction of CCR1 expression at relapse, may be associated with poor prognosis in MM 
patients treated with bortezomib-based therapeutic regimens. This is in accordance with 
our previous microarray analysis of CCR1 expression in patients enrolled in the Total 
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Therapy 2 and Total Therapy 3 clinical trials which included bortezomib-based regimens, 
where we found that elevated CCR1 expression at diagnosis was associated with poor 
prognosis.19 Previous analysis of patients in the Total Therapy 3 trial showed that 
expression of the transcription factor MAF is also associated with poor prognosis in these 
patients.37,38 Furthermore, in overexpression and knockout studies, MAF expression was 
shown to increase resistance to bortezomib in MM cell lines.37 Interestingly, expression of 
CCR1 is known to be driven by MAF in human MM cell lines.37,39 The data presented here 
suggest that elevated CCR1 could, in part, mediate the prognostic disadvantage of elevated 
MAF expression observed in these previous studies. 
 
The primary ligands for CCR1 are CCL3 and CCL5,40 with CCL3 being both the most 
potent CCR1 ligand and the most highly expressed CCR1 ligand in MM PCs.41-44 Previous 
studies have shown inconsistent results with respect to the potential chemoprotective 
effects of CCL3. Lentzsch and colleagues demonstrated that addition of CCL3, even at 
very high concentrations, did not affect the response of the human MM cell line MM.1S to 
dexamethasone or melphalan in vitro.18 In contrast, treatment with a CCL3-neutralising 
antibody or siRNA-mediated CCL3 knockdown has been shown to increase the cytotoxic 
effect of bortezomib in a human immortalised B-cell line in vitro.20 Furthermore, a 
melphalan-resistant RPMI-8226 cell line, which expressed abundant CCL3, could be re-
sensitised to melphalan therapy with the addition of the CCL3-neutralising antibody.20 
While these studies suggest that CCL3 signalling can play a role in resistance to 
therapeutics, here we show that MM PC sensitivity to bortezomib is influenced by CCR1 
expression in a CCL3-independent manner. To this end, we observed that neither siRNA-
mediated knockdown of CCL3 nor addition of recombinant CCL3 influenced the 
sensitivity of human and murine MM cell lines to bortezomib. As 5TGM1, U266 and 
OPM2 cells do not express the alternate CCL3 receptor, CCR5, or high levels of the other 
CCR1 ligand CCL5 (data not shown), the lack of effect of CCL3 knockdown is unlikely to 
be due to redundancy in chemokine ligand-receptor binding. Notably, a number of G-
protein coupled receptors, including CCR1, have been shown to be capable of adopting an 
active conformation and inducing downstream signalling in the absence of ligand.45,46 
Studies in human and murine leukocytes have suggested that CCR1 can take on an active 
conformational state in the absence of ligand, enabling G-protein-dependent signalling that 
leads to increased F-actin polymerisation and migration, which can be blocked using a 
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CCR1 inhibitor.46 This suggests that the CCL3-independent effects of CCR1 expression 
observed here may be attributable to constitutive CCR1 signalling in the absence of ligand. 
 
Adhesion to BM stromal cells (BMSCs) and extracellular matrix, mediated by integrin 
α4β1 (also known as very late antigen 4, VLA-4) and CD44, has been implicated in the 
resistance to the anti-MM drugs vincristine,47 dexamethasone,47 lenolidamide,48 
doxorubicin49 and melphalan49 in a process known as cell adhesion-mediated drug 
resistance (CAMDR). However, co-culture of MM PCs with BMSCs has been shown to 
have minimal effect on response to bortezomib.47 Bortezomib was shown to decrease the 
expression of the α4 (also known as CD49d) subunit of integrin α4β1, suggesting that 
bortezomib treatment may counteract the effects of CAMDR, thereby sensitising MM cells 
to other antimyeloma agents.47 Indeed, addition of bortezomib decreased the effects of 
CAMDR for vincristine or dexamethasone and increased tumour cell death in vitro.47 In 
the studies presented here, we found that NSG mice injected with OPM2-CCR1-KO-1 
cells have significantly lower tumour burden compared with mice inoculated with OPM2-
EV-1 cells when treated with bortezomib. As we also observed that OPM2-CCR1-KO-1 
cells are more sensitive to bortezomib therapy compared with EV controls in cell 
suspension in vitro, this suggests that CCR1 mediates resistance to bortezomib in part 
through a CAMDR independent mechanism. 
 
There is strong evidence to suggest that the response of MM PCs to bortezomib is 
dependent on activation of the IRE1 pathway and the splicing of XBP1 to its active form, 
XBP1s.12,26,27 In support of this, decreased IRE1 or XBP1 levels have previously been 
suggested to be associated with increased resistance to bortezomib both in patients and in 
cell line models.26,27 Leung-Hagesteijn and colleagues showed that levels of XBP1s target 
gene expression in BM MM PCs from MM patients pre-treatment predicted the response to 
single-agent bortezomib therapy, with significantly lower expression in patients who 
relapsed following bortezomib treatment compared with patients who had a complete 
response.26 Similar results were seen in an independent study, showing that BM MM PC 
total (spliced and unspliced) XBP1 mRNA prior to bortezomib treatment was significantly 
lower in patients that subsequently did not respond to bortezomib, compared with 
bortezomib-responsive patients.27 Evidence also suggests siRNA- or shRNA-mediated 
knockdown of either XBP1s12,26 or IRE126 in human and murine MM cell lines increases 
resistance to bortezomib in vitro. Consistent with this, we have shown an association 
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between CCR1 expression, decreased IRE1 expression and bortezomib resistance in MM 
cell lines. In MM PCs lines that express CCR1 (OPM-2-EV-1 and 5TGM1-CCR1 cells), 
there was considerably lower basal stress (as seen by IRE1α) than CCR1-negative cells. 
Thus, CCR1 expression allows the MM PCs to better tolerate subsequent stresses, hence 
are more resistant to bortezomib. In support of this, our data suggests that decreased IRE1 
expression with CCR1 expression in 5TGM1 cells was associated with decreased 
activation of apoptosis-associated signalling pathways downstream of IRE1, in response to 
bortezomib treatment, as reflected by decreased induction of CHOP and p-JNK levels. 
However, this finding was not replicated in OPM2 cells. This may be due to the early 
timepoint (6 hours) used here. In addition, using RNA-sequencing data from MM patients, 
we found that CCR1 expression inversely correlates with IRE1 expression, supporting our 
in vitro findings that CCR1 downregulates IRE1 expression. CCR1 activation results in the 
phosphorylation and activation of the PI3K/AKT signalling pathway. Notably, AKT has 
been suggested to regulate the UPR.50,51 Mimura and colleagues showed that inhibition of 
AKT increased the IRE1 and p-IRE1 levels in a dose-dependent manner in human MM cell 
lines.52 In further support of this, inhibition of AKT has been shown to increase the 
sensitivity of MM cell lines to bortezomib in vitro and in vivo in multiple studies.52-54 
Taken together, these data suggest a potential mechanism whereby CCR1 may lead to 
decreased sensitivity of MM PCs to bortezomib therapy via activation of the AKT 
signalling pathway and, subsequently, decreased IRE1 expression.  
 
In summary, this study identifies for the first time a novel role for CCR1 in the resistance 
of MM PC to bortezomib therapy, through a mechanism that may involve decreased 
expression of IRE1. Furthermore, our study shows that elevated CCR1 expression at 
diagnosis and/or following induction of CCR1 expression at relapse is associated with poor 
prognosis in MM patients treated with bortezomib. These results are of potential 
importance as bortezomib is commonly used in frontline and relapse therapeutic regimens, 
suggesting that CCR1 may be a useful biomarker to predict the response to bortezomib 
therapy. Future studies examining whether CCR1 inhibition can re-sensitise resistant MM 
PC to bortezomib therapy, and to investigate whether CCR1 plays a role in sensitivity to 
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Supplementary Table 3.1. Real-time qPCR human and mouse primer sequences
  Forward Reverse 
ACTB 5′ - GATCATTGCTCCTCCTGAGC - 
3′ 
5′ - GTCATAGTCCGCCTAGAAGCAT 
- 3′ 
ActB 5′ - TTGCTGACAGGATGCAGAAG - 
3′ 
5′ - AAGGGTGTAAACGCAGTTC - 3′ 
ERN1 5′ - CGGGAGAACATCACTGTCCC - 
3′ 
5′ - CCCGGTAGTGGTGCTTCTTA - 3′ 
Ern1 5′ - 
CCCTGATAGGTTGAATCCTGGCTA
TGTG - 3′ 
5′ - 
AATCTATGCGCTAATCTGCTGGCC
TCTG - 3′ 
XBP1 5′ - TTGTCACCCCTCCAGAACATC - 
3′ 
5′ - TCCAGAATGCCCA ACAGGAT - 
3′ 
Xbp1 5′ - TGGCCGGGTCTGCTGAGTCCG - 
3′ 
5′ - GTCCATGGGAAGATGTTCTGG - 
3′ 
XBP1s 5′ - TGCTGAGTCCGCAGCAGGTG - 
3′ 
5′ - GCTGGCAGGCTCTGGGGAAG - 
3′ 
Xbp1s 5′ - CTGAGTCCGAATCAGGTGCAG 
- 3′ 




5′ - GGCTCGGTATTCCCCTTCCT - 3′ 5′ - 
AGTAGCCCTCCGATAATAAGCAA - 
3′ 
Dnajc3 5′ - AAGGGAAGCTTGACGAAGCA - 
3′ 
5′ - TAGCAGCAGTGTAATCGCA - 3′ 
CHOP 5′ - 
AGAACCAGGAAACGGAAACAGA - 
3′ 
5′ - TCTCCTTCATGCGCTGCTTT - 3′ 
Chop 5′ - CCACCACACCTGAAAGCAGAA 
- 3′ 
5′ - AGGTGAAAGGCAGGGACTCA - 
3′ 
HSPA5 5′ - 
TGTTCAACCAATTATCAGCAAACT









T - 3′ 






Atf4 5′ - 
CCTAGGTCTCTTAGATGACTATCT
GGAGG - 3′ 
5′ - 
CCAGGTCATCCATTCGAAACAGAG
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The chemokine receptors are a family of nineteen G-protein coupled receptors that 
modulate cell migration and trafficking via their specificity for chemoattractant 
cytokines, known as chemokines. Previous studies have shown functional roles for 
some chemokine receptors in the pathogenesis of the haematological malignancy 
multiple myeloma (MM), but a comprehensive assessment of the association between 
elevated MM plasma cell (PC) chemokine receptor expression and patient prognosis has 
not been conducted. We have previously identified that the C-C chemokine receptor 1 
(CCR1) is associated with poorer prognosis in newly diagnosed MM patients. Here, we 
examined the expression of the full repertoire of chemokine receptors expressed in 
CD138-selected BM MM PCs from newly diagnosed MM patients and investigated the 
association between increased expression and overall survival. Initially, we interrogated 
a publicly available microarray dataset consisting of BM PC gene expression analysis 
from 142 newly diagnosed MM patients (E-TABM-1138) and found that CCR2, CCR5 
and CXCR4 were expressed in the majority of patients, CCR1, CCR10, CXCR1, CXCR3 
and CX3CR1 were expressed in a subset of patients, while CCR3, CCR4, CCR6, CCR7, 
CCR8, CCR9, CXCR2, CXCR5, CXCR6, CXCR7 and XCR1 had low or undetectable 
expression in most patients. Assessment of the association between elevated receptor 
expression with overall survival found that apart from CCR1, only CCR10 expression 
was associated with poorer prognosis. Approximately 50% of patients expressed 
CCR10, and patients with above median CCR10 expression had significantly decreased 
overall survival when compared with patients without elevated levels (p=0.034, hazard 
ratio: 2.3 [95% CI: 1.1-4.8]). We further assessed CCR10 protein expression using flow 
cytometry on CD38++/CD138+/-/CD45lo/CD19- BM MM PCs from 27 newly diagnosed 
MM patients and found that CCR10 was highly expressed in 26.9% (8/27) of MM 
patients. Furthermore, there was a trend towards elevated expression of CCR10 protein 
being associated with decreased overall survival, although this did not reach statistical 
significance (p=0.051, hazard ratio: 4.4 [95% CI: 0.99-19]). CCR10 expression was also 
not significantly different between tumour cells from patients with the precursor 
condition monoclonal gammopathy of undetermined significance (MGUS) and those 
with MM as assessed by flow cytometry (n=6 MGUS and 27 MM patients) and 
microarray analysis (n=5 MGUS and 155 MM, E-MTAB-363; n=11 MGUS and 133 
MM, E-GEOD-16122). In addition, CCR10 expression, as assessed by flow cytometry 
and microarray analysis (E-TABM-1138), did not correlate with high risk clinical 
CHAPTER 4 
 124 
prognostic factors or cytogenetic subgroups. Collectively, our studies suggest that 
CCR10 may be a novel independent prognostic marker in MM. Future studies are 
warranted to confirm the potential utility of CCR10 as a novel prognostic marker in 




Chemokines are small, chemoattractant cytokines that bind to specific G-protein-
coupled 7-span transmembrane receptors and play a critical role in the selective 
recruitment of leukocytes to target tissues.1 Chemokines can be classified into four 
groups (XC, CC, CXC and CX3C) based on the number and arrangement of conserved 
cysteine (C) residues near the N-terminus. Their respective receptors are classified 
based on their affinity for the classes of ligand: one known XC chemokine receptor 
(XCR1), ten CC receptors (CCR1-10), seven CXC receptors (CXCR1-7), and one 
CX3C receptor (CX3CR1).  Chemokine ligands have been shown to have redundancy 
in their affinity for the various receptors, while one chemokine receptor may be able to 
transduce the signals of multiple ligands (e.g. the CC chemokine receptor 10 (CCR10) 
has two ligands, CC chemokine ligands CCL27 and CCL28), ligands may be able to 
bind to multiple receptors (e.g. CCL3 is a ligand for both CCR1 and CCR5). To achieve 
specificity and direct leukocyte recruitment, chemokine expression is regulated in a 
temporal and spatial manner, and receptor expression is often tissue- and/or cell-type 
specific.2  
 
Chemokines and their receptors have been shown to be involved in the migration and 
growth of tumour cells in multiple haematological malignancies and solid tumours.3-4  
Multiple myeloma plasma cells (MM PCs) express a variety of chemokine receptors 
and secrete several chemokines,5 highlighting the need to assess the role of these 
receptors in MM pathogenesis and identify which receptors would be useful therapeutic 
targets to slow disease progression or novel prognostic markers. BM MM PCs from 
patients have been demonstrated to express CCR1, CCR2, CCR5, CXCR3 and CXCR4, 
while MM cell lines have been shown to express CCR1, CCR2, CCR6, CCR10, 
CXCR3, CXCR4 and CXCR6.5-11  Previous studies have demonstrated key roles for 
chemokine receptors expressed on MM PCs in tumour cell migration and proliferation. 
The interaction of CXCR4 with its ligand CXCL12 (also known as stromal cell-derived 
factor 1 (SDF-1)) is well-characterised to be crucial in the homing of MM PCs from the 
circulation to the BM12,13 and their subsequent retention within the BM.14,15 BM stromal 
cells (BMSCs) abundantly express CXCL12,16 creating a concentration gradient that 
directs entry of MM PCs into the BM12,13 and mediates strong MM PC-BMSC 
adhesion.14,15 In Chapter 2, we demonstrated that CCR1 is a driver of MM PC 
dissemination in vivo. In multiple studies, CCL3, the ligand for CCR1 and CCR5, has 
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been shown to be a potent inducer of MM PC migration in vitro.5,9 Similarly, the ligands 
for CCR2 (CCL2, also known as monocyte chemotactic protein 1 (MCP-1), and MCP-2 
and -3),7,17 CXCR1 (CXCL8, also known as interleukin 8 (IL-8)),18  CXCR3 (CXCL9, 
also known as monocyte/macrophage-activating IFN-g-inducible protein (Mig), 19; 
CXCL10, also known as IFN-g-inducible 10 kDa protein (IP10),5,19; and CXCL11, also 
known as interferon-inducible T-cell alpha chemoattractant (I-TAC),19) and CXCR6 
(CXCL6)6 have also been shown to induce the chemotaxis of MM cell lines and patient-
derived MM PCs in vitro. In addition, there is some evidence that chemokines can 
increase MM PC proliferation in vitro. For example, CXCL8 has also been shown to 
induce MM cell line and patient-derived MM PC proliferation in vitro,18 while CXCL12 
induces a modest increase in proliferation in MM cell lines and patient MM PCs.18,20 
While we demonstrated in the preceding chapters that CCL3 does not affect MM PC 
proliferation in two MM cell lines in vitro, CCL3 has also been suggested to induce 
proliferation of some MM cell lines in vitro.21 Additionally, CXCL12/CXCR4 has been 
shown to drive resistance to chemotherapy, through cell-adhesion mediated 
resistance.22,23 Furthermore, we found that CCR1 expression decreases the sensitivity of 
MM cell lines to bortezomib therapy (Chapter 3). While these studies suggest that some 
chemokines and their receptors may play a functional role in MM, the role of the other 
chemokine receptors in MM pathogenesis remains to be elucidated. Furthermore, a 
systematic analysis of the expression of all chemokine receptors in MM patients and 
their association with patient survival has not been conducted.  We have previously 
shown using in silico analysis that elevated BM MM PC CCR1 expression is associated 
with a poorer prognosis in newly diagnosed MM patients.9 In contrast, newly diagnosed 
patients with detectable BM MM PC CCR1 expression by flow cytometry were shown 
to have a better prognosis than CCR1-negative patients.24 Additionally, previous studies 
suggest that elevated MM PC expression of CXCR4,24,25 or CCR224, as assessed by 
flow cytometry, was associated with  better prognosis in newly diagnosed MM patients. 
Here, we systematically analysed the expression of chemokine receptors in newly 
diagnosed MM patients using microarray analyses and identified CCR10 as a novel 
independent prognostic marker. We further assessed CCR10 protein expression in 
MGUS and MM patients using multicolour flow cytometry. Lastly, we assessed 




4.3. Materials and Methods 
4.3.1. Publicly available microarray data 
Microarray analysis of publicly available data was conducted as previously described.26 
For analysis of CCR1, CCR2, CCR3, CCR4, CCR5, CCR6, CCR7, CCR8, CCR9, 
CCR10, CX3CR1, CXCR1, CXCR2, CXCR3, CXCR4, CXCR5, CXCR6, CXCR7 and 
XCR1 expression in CD138-selected BM plasma cells from newly diagnosed MM 
patients and analysis of the association of elevated receptor expression with overall 
survival the dataset E-TABM-1138 (n=142)27 was used. For this dataset, expression of 
log2(250) was used as the cut-off for high or low expression. For analysis of CCR10 
expression in CD138-selected BM PCs from newly diagnosed MGUS or MM patients 
or normal controls, two independent microarray datasets were used: E-GEOD-16122 
(normal, n=5; MGUS, n=11; MM, n=133)28 and E-MTAB-363 (normal, n=5; MGUS, 
n=5; MM, n=155).29 E-MTAB-363 and E-TABM-1138 were conducted on Affymetrix 
GeneChip Human Genome U133 plus 2.0 arrays; E-GEOD-16122 was conducted on 
U133A arrays. Raw microarray data (CEL files) were downloaded from ArrayExpress 
(EMBL-EBI) or Gene Expression Omnibus (GEO; NCBI) and were normalised by 
RMA using the bioconductor package (affy)30 in R (version 3.03) and log2 transformed, 
as previously described.9  
 
4.3.2. Publicly available RNA sequencing data 
RNA-sequencing data was obtained from the Multiple Myeloma Research Foundation 
(MMRF) CoMMpass (MMRF-COMMPASS) dataset, accessed via the NIH NCI GDC 
Data Portal (9 August 2019). Gene expression data (expressed as fragments per kilobase 
per million mapped reads [FPKM]) for CD138-selected BM PC was included from 762 
MM patients at initial diagnosis who had not received previous therapy [median age: 63 
years (range 27–88); male:female ratio 1.69:1]. 
 
4.3.3. Patient samples 
Ethical approval for this study was obtained from the University of Freiburg Medical 
Centre Ethics Review Committee and all patients provided written, informed consent, in 
accordance with the Declaration of Helsinki. Posterior superior iliac spine BM aspirates 
(n=27) were collected from symptomatic MM patients at initial diagnosis that had not 
received previous therapy [median age: 68 years (range 49–84); male:female ratio 
1.15:1]. All MM patients fulfilled the diagnostic criteria for active MM.31 A further 6 
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patients, defined as MGUS31 were also examined. The patients presented at the 
University of Freiburg Medical Centre (Freiburg, Germany) between 15 June 2007 and 
30 April 2019. BM was collected in K-EDTA tubes and BM mononuclear cells 
(BMMNC) were isolated by density gradient centrifugation (FICOLL) and were 
cryopreserved prior to use as described previously.32 Overall survival was calculated 
from the date of BM collection until death, by any cause. Patients who were lost to 
follow up were censored at the date of last contact. For MM patients with follow up 
available (n=25), median follow up was 23 months (range: 4 – 133). Information 
regarding patient outcomes was last updated in January 2020.  
 
4.3.4. Flow cytometry 
Cell surface CCR10 expression was assessed and  viable CD38++/CD138+/-
/CD45lo/CD19-  malignant PCs were sorted from BM aspirates of MGUS (n=6) and MM 
(n=27) patients by multicolour flow cytometry (FACSARIA III; BD Biosciences) as 
previously described.9 Briefly, 3x105 mononuclear cells per test were stained with an 
anti-CCR10-PE (REA326; Miltenyi Biotech, Bergisch Gladbach, Germany) antibody, 
or no PE-conjugated primary antibody [fluorescence minus one (FMO) control], in 
combination with CD38-PE-Cy7 (HIT2; BioLegend, San Diego, CA), CD138-
AlexaFluor-647 (B-A38; BioRad, Hercules, CA) CD45-FITC (J.33; Beckman Coulter, 
Brea, CA), and CD19-Brilliant Violet 421 (HIB19; BioLegend) antibodies. Cells were 
stained with the viability dye hydroxystilbamidine (FluoroGold; Invitrogen, Life 
Technologies, Carlsbad, CA) immediately before analysis. Viable, single cells were 
gated on the basis of FSC and SSC characteristics and FluoroGold negativity and MM 
PCs were identified as CD38-bright and CD138-positive or CD138-negative cells. As 
CD138 is frequently downregulated on frozen specimens, CD138 positivity was not 
absolutely required for defining the MM PC population. Contaminating cells were 
subsequently excluded by gating on the CD45-low and CD19-negative population. A 
minimum of 100 cells was required to fulfil these criteria to be identified as a PC 
population. A minimum of 5x104 total nucleated cells were analysed per test. CCR10 
expression was quantitated as the change in the median fluorescence intensity (DMFI), 
defined as the difference in MFI between the CCR10-stained sample and the FMO 
control. High CCR10 expression, delineated based on two distinct populations of MM 




4.3.5. Real-time quantitative PCR (qPCR) 
Total RNA was isolated from a minimum of 5 x 104 viable CD38++/CD138+/-
/CD45lo/CD19- malignant PCs sorted from BM aspirates of MGUS (n=3) and MM 
(n=12) by multicolour flow cytometry (FACSARIA III; BD Biosciences). Isolated RNA 
was DNAse treated using the RNeasy Micro Kit as per manufacturer’s instructions 
(Qiagen, Hilden, Germany), and cDNA was synthesised using Sensiscript RT Kit as per 
manufacturer’s instructions (Qiagen). qPCR was performed using a CFX Connect Real-
Time PCR machine (BioRad, Hercules, CA) using the primers for ACTB (Fwd 5’- 
GATCATTGCTCCTCCTGAGC -3; Rev 5’- GTCATAGTCCGCCTAGAAGCAT -3’) 
and CCR10 (Fwd 5’- CCTGCTGCTGGATACTGCC -3’; Rev 5’- 
TCACCAGCAGTGCGACAT -3’). Changes in gene expression were calculated 
relative to ACTB using the 2-DCt method.33 
 
4.3.6. Statistical Analyses 
Unless otherwise described, statistical analysis was performed using GraphPad Prism 
(version 8.1; GraphPad Software). Overall and progression-free survival was assessed 
using Kaplan–Meier curves; comparisons between groups were made using the logrank 
(Mantel–Cox) test and the Mantel–Haenszel hazard ratio. For comparison between 
patient groups, groups were compared using a Kruskal-Wallis or Mann-Whitney test. 
For all other experiments, groups were compared using a Mann-Whitney test. 
Univariate and multivariate analyses were conducted using SPSS version 26. Initially, 
univariate Cox regressions were conducted to identify factors that were significantly 
associated with survival (p < 0.1). These factors were then included in multivariate Cox 
proportional hazards models to determine if these factors affected the association 
between CCR10 expression and overall survival using the dataset E-TABM-1138. 




4.4.1. Chemokine receptor expression in MM PCs isolated from newly diagnosed 
MM patients 
Using in silico analysis of the publicly available microarray dataset E-TABM-1138 
consisting of 142 newly diagnosed MM patients enrolled in the Total Therapy 3 (TT3) 
trial,27 we systematically assessed the expression of chemokine receptors on BM 
CD138+ PCs isolated from newly diagnosed MM patients (Figure 4.1). We found that 
CCR2, CCR5 and CXCR4 were expressed (defined as > log2(250) expression) in the 
majority of MM patients (CCR2: n=138/142 patients, 97.2%; CCR5: n=138/142, 97.2%; 
CXCR4: n=141/142, 99.3%). Furthermore, CCR1 (n=67/142, 47.0%), CCR10 
(n=70/142, 49.3%), CXCR1 (n=49/142, 34.5%), CXCR3 (n=41/142, 28.9%) and 
CX3CR1 (n=18/142, 12.7%) were expressed in a moderate number of patients. In 
contrast, CCR3 (n=0/142, 0%), CCR4 (n=4/142, 2.8%), CCR6 (0/142, 0%), CCR7 
(n=4/142, 2.8%), CCR8 (0/142, 0%), CCR9 (0/142, 0%), CXCR2 (0/142, 0%), CXCR5 
(6/142, 4.2%) CXCR6 (0/142, 0%), CXCR7 (0/142, 0%), and XCR1 (0/142, 0%) were 
expressed in a minority of patients or were not detectable in any patients analysed. 
Similar results were observed in an independent cohort of MM patients (n = 762) 
analysed by RNA-sequencing (CoMMpass dataset; Supplementary Figure 4.1). 
 
4.4.2. CCR10 expression in BM MM PCs is associated with poorer prognosis in 
newly diagnosed MM patients 
We have shown that 64.3% (18/28) (Chapter 3) to 81% (13/16)9 of newly diagnosed 
MM patients express detectable CCR1 by flow cytometry on isolated BM MM PCs. 
Furthermore, using this dataset, we have shown that elevated CCR1 expression in 
CD138+ BM PCs is associated with poorer prognosis in newly diagnosed MM patients.9 
To determine whether expression of other chemokine receptor(s) have prognostic value 
in MM, we investigated whether BM PC expression of chemokine receptors was a 
significant predictor of overall survival in newly diagnosed patients. For highly 
expressed receptors CCR2, CCR5 and CXCR4, which were expressed in the majority 
(>97%) of patients, patients were grouped into high- and low-expressing groups based 
on median expression for that receptor. For all other receptors, which were expressed in 
less than 40% of patients, patients were classed into receptor-positive and -negative 
groups based on expression above the cut-off of log2(250). These analyses showed that 

















































Figure 4.1. Expression of chemokine receptors in newly diagnosed MM patients. 
In silico analysis was performed on a publicly available microarray dataset (E-TABM-
1138) analysing gene expression in CD138
+
 PC isolated from newly diagnosed MM 
patients (n = 142 patients). Expression less than 7.966 (log2(250); in grey) was classed 

























































































































Figure 4.2. Association of chemokine receptors expressed on MM PCs with 
survival of newly diagnosed MM patients. Kaplan-Meier plots of overall survival 
are shown for newly diagnosed MM patients, stratified based on median CD138
+
 PC 
expression of  (A) CCR2 (B) CCR5 and (C) CXCR4, or based on positive- or negative-
expression of (D) CXCR1, (E) CXCR3 and (F) CX3CR1 expression, or median 
expression of (G) CCR10,  derived from microarray dataset E-TABM-1138 (n = 142 
patients).  






















































































































(p=0.43, HR=0.74 [95% CI: 0.35-1.55]; Figure 4.2B) and CXCR4 (p=0.21, HR=0.65 
[95% CI: 0.33-1.3]; Figure 4.2C) expression were not significantly associated with 
overall survival. Additionally,  expression of CXCR1 (p=0.17, HR=1.7 [95% CI: 0.77-
3.7; Figure 4.2D), CXCR3 (p=0.72, HR=0.86 [95% CI: 0.38-2.0]; Figure 4.2E), 
CX3CR1 (p=0.55, HR=1.2 [95% CI: 0.38-3.7]; Figure 4.2F) in MM patients was not 
associated with any effect on overall survival. Notably, however, above median CCR10 
expression was significantly associated with poor prognosis (p=0.034; HR=2.3 [95% 
CI: 1.1-4.8]; Figure 4.2G). The low number of positive patients precluded further 
investigation of the CCR4, CCR7 and CXCR5 chemokine receptors. 
 
4.4.3. CCR10 is expressed in MGUS and MM patients and normal PCs 
To further investigate CCR10 expression in BM PCs of MGUS and MM patients as 
well as normal controls, we  used in silico analysis of two independent publicly 
available microarray datasets E-MTAB-363 (n=5 MGUS, 155 MM patients and 5 
normal controls) and GEOD16122 (n=11 MGUS,133 MM patients and 5 normal 
controls). CCR10 was found to be consistently expressed across all groups of patients 
and normal controls (p=0.31, E-MTAB-363, Figure 4.3A; p=0.11, GEOD16122, Figure 
4.3B). We confirmed this finding by sorting CD38++/CD138+/-/CD45lo/CD19- malignant 
PCs (Figure 4.3C) from BM samples from 3 newly diagnosed MGUS and 12 newly 
diagnosed MM patients using flow cytometry. qPCR analysis showed that CCR10 
mRNA was detectable in all MGUS and 83.3% (10/12) of MM patients, with no 
difference in expression levels between patient groups (p=0.63, Figure 4.3D). To assess 
CCR10 protein expression, we utilised flow cytometry of CD38++/CD138+/-
/CD45lo/CD19- BM PCs (Figure 4.3C) in 27 newly diagnosed MM and 6 MGUS 
patients. MM patients were grouped into two distinct subgroups, with high CCR10 
protein expression (DMFI > 750) being observed in 29.6% (8/27) of MM patients and 
0% (0/6) of MGUS patients (Figure 4.4A). Notably, CCR10 protein expression was not 
significantly different between MGUS (DMFI median: 171.4, range: 29.5-489.8) and 
MM (DMFI median: 369.1, range: 76.80-2254) patients (p=0.0573, Figure 4.4B).  
 
Our data suggests that elevated CCR10 expression in BM MM PCs is associated with 
poor prognosis of newly diagnosed MM patients. In order to further analyse the 
association between CCR10 protein expression and poor survival, patients were 

















































Figure 4.3. CCR10 is expressed by PCs from MGUS and MM patients and healthy 
donors. A. In silico analysis was performed on publicly available microarray dataset 
(E-MTAB-363) analysing gene expression of CCR10 in CD138+ PCs isolated from 
MGUS (n = 5) and MM (n = 155) patients and normal PCs from healthy donors (n = 5). 
Expression below 6.644 (log2(100); in grey) was classed as not expressed. B. In silico 
analysis was performed on publicly available dataset analysing gene expression of 
CCR10 in CD138+ PCs isolated from MGUS (n = 11) and MM (n = 133) patients and 
healthy controls (n = 5) (E-GEOD-16122). Expression below 6.644 (log2(100); in grey) 
was classed as not expressed. C. MM PCs were identified in the BM of newly diagnosed 
MGUS or MM patients as viable cells based on forward (FSC) and side (SSC) scatter 





followed by exclusion of normal PCs that are CD45 and CD19 positive. A representative 









 BM malignant PCs isolated from newly diagnosed 















































































































































































Figure 4.4. CCR10 protein expression is associated with decreased overall survival 
in newly diagnosed MM patients. A. CCR10 expression (unfilled histogram) and PE 








 BM MM 
PCs is shown for 4 representative newly diagnosed MM patients. B. CCR10 protein 
expression (DMFI) on CD38++/CD138+/-/CD45lo/CD19- BM malignant PCs is shown for 
newly diagnosed MGUS (n=6) and MM (n=27) patients analysed by flow cytometry. 
Expression below DMFI of 750 (based on two distinct MM PC populations; in grey) 
was classed as low CCR10 expression. Graph depicts median with interquartile range, 
showing all data points. C. Kaplan-Meier plot of overall survival is shown for 25 newly 

































































flow cytometry (using the cut-off DMFI 750), and patient overall survival was assessed. 
For the 25 patients with clinical follow up (median follow up: 23 months; range: 4–
133), there was a trend towards high CCR10 expression and poorer overall survival, 
however this did not reach significance (p=0.051, HR=4.4 [95% CI: 0.99-19], median 
survival: 90 months vs not reached, Figure 4.4C).  
  
4.4.4. CCR10 is an independent prognostic indicator in MM 
We next assessed whether the poor prognosis associated with elevated CCR10 
expression was associated with particular cytogenetic or clinical features in newly 
diagnosed MM patients. Recurring chromosomal abnormalities are a common feature in 
MM tumours, with t(4;14), t(14;16), t(14;20), del 17p and amp 1q being associated with 
poor prognosis, while t(11;14), t(6;14) and hyperdiploidy are associated with better 
prognosis.35 Patients in the E-TABM-1138 gene expression dataset were subdivided 
based on the molecular subgroups described by the University of Arkansas for Medical 
Science (UAMS) molecular classification system: CD1 and CD2 (characterised by high 
CCND1 and CCND3 expression, corresponding to t(11;14) and  t(6;14)), MF 
(characterised by high expression of MAF and MAFB proto-oncogenes, as seen in 
t(14;16) and t(14;20, respectively), MS (associated with high FGFR3 and MMSET 
expression, associated with t(4;14)), HY (corresponding with the hyperdiploidy group), 
PR (associated with expression of numerous cell cycle and proliferation-related genes), 
and LB (Low bone disease; associated with lower number of magnetic resonance 
imaging (MRI)-defined focal lesions). While there were no statistically significant 
differences in the expression between UAMS subgroups in the E-TABM-1138 dataset, 
there were trends toward higher expression of CCR10 in patients in the CD1, HY and 
PR subgroups (Figure 4.5). We found that CCR10 was expressed (defined as > 
log2(250) expression) in the majority of patients in the CD1, HY and PR subgroups 
(CD1: n=2/3 patients, 66.7%; HY: n=28/40, 70.0%; PR: n=10/15, 66.7%), a moderate 
proportion of patients in the CD2, MS and LB subgroups (CD2: n=4/11 patients, 36.4%; 
MS: n=6/13, 46.2%; LB: n=8/18, 44.4%), and in only one patient in the MF subgroup 
(n=1/10, 10%) (Figure 4.5).The relatively low incidence of poor prognostic cytogenetics 
precluded analysis of individual cytogenetic abnormalities in the CCR10 protein 
expression cohort (Table 4.1). However, we were able to search for any association 
between CCR10 expression and the presence of any poor cytogenetic prognostic 

















































Figure 4.5. CCR10 is expressed in most newly diagnosed MM cytogenetic 
subgroups. Expression of CCR10 stratified based on UAMS subgroup: t(11;14) (CD1), 
t(6;14) (CD2), t(14;16) and t(14;20) (MF), t(14;4) (MS) translocations, hyperdiploidy 
(HY), low bone disease (LB) and proliferation (PR) groups. Derived from microarray 





































Table 4.1. Baseline MM patient cytogenetic abnormalities grouped according to 
BM MM PC CCR10 protein expression 
#c2 test or Fisher’s exact test as appropriate
*based on the International Myeloma Working Group (IMWG) criteria (2016)
Cytogenetic abnormalities Flow cohort (n=27) 





Hyperdiploidy    
    Number 12/19 2/6 N/A     Percentage 63 33 
Deletion 13q    
    Number 2/19 1/6 N/A     Percentage 10.5 16.7 
Amplification 1q    
    Number 2/19 1/6 N/A     Percentage 10.5 16.7 
t(14;16)    
     Number 0/19 1/6 N/A      Percentage 0 16.7 
t(11;14)    
     Number 0/19 1/6 N/A      Percentage 0 16.7 
t(4;14)    
    Number  2/19 0/6 N/A     Percentage 10.5 0 
Overall poor cytogenetics*    




poor cytogenetics35 (p=0.61, Table 4.1). To determine whether CCR10 is an 
independent prognostic indicator in MM, we assessed CCR10 expression, known 
clinical prognostic factors34 and high-risk chromosomal abnormalities35  for their 
association with overall patient survival (n=142 newly diagnosed patients, E-TABM-
1138; Table 4.2). On univariable analysis, above median CCR10, elevated serum 
β2-microglobulin (> 5.5mg/L), anaemia (haemoglobin < 10g/dl) and high-risk gene 
expression signatures (MS, MF and PR subgroups) were associated with inferior 
survival (p<0.05, Table 4.2). These factors were then included in the multivariable 
analysis to determine if they affected the association between CCR10 expression and 
overall survival. Notably, in multivariate analysis, CCR10 retained its prognostic 
significance (p=0.014, Table 4.2). As CCR10 protein expression was not significantly 
associated with poorer prognosis, this precluded our ability to perform multivariable 
analysis on this cohort. However, we did observe that the incidence of none of the high-
risk clinical features of patient age (>65 years), β2-microglobulin (>5.5mg/L), serum 
albumin (<35 g/L) or higher stage of the international staging system (ISS; based on 
β2-microglobulin and serum albumin) was significantly different in patients with high 
versus patients with low CCR10 protein expression (n=27 patients, p>0.05, Table 4.3).  
 
 
Factors Univariable Analysis Multivariable Analysis 
 p-value HR 95% CI p-value HR 95% CI 
CCR10 0.04 2.30 1.04 5.09 0.014 2.81 1.24 6.37 
Age > 65 years 0.62 0.77 0.32 1.97     
b-2-microglubulin > 5.5 mg/L 0.021 2.45 1.15 5.24 0.48 1.36 0.58 3.16 
Serum albumin < 35 g/L    0.54 1.31 0.56 3.08     
Haemoglobin < 10 g/dl 0.001 3.52 1.67 7.45 0.006 3.34 1.41 7.90 
High-risk cytogenetics* (MF, 
MS and PR subgroups#) 
0.044 2.16 1.02 4.57 0.186 1.70 0.78 3.71 
Table 4.2. Univariable and multivariable analysis of overall survival associated 
with CCR10 and other factors
*based on the International Myeloma Working Group (IMWG) criteria (2016)
#UAMS molecular classification
Table 4.3. Baseline MM patient risk factors grouped according 
to BM MM PC CCR10 protein expression 
Risk factors Flow cohort (n=27) 




Age >65 years    
    Number 8/19 2/8 0.67     Percentage 42.1 25 
b-2-microglubulin >5.5 mg/L    
    Number 5/18 2/8 >0.99     Percentage 27.8 25 
Serum albumin < 35 g/L    
    Number 6/18 1/8 0.37     Percentage 33.3 12.5 
ISS Stage    
I Number 6/17 5/8 
0.39 
Percentage 35.3 62.5 
    
II Number 6/17 1/8 Percentage 35.3 12.5 
    
III Number 5/17 2/8 Percentage 29.4 25 
Paraprotein    
IgG Number 14/19 3/8 0.10 Percentage 73.7 37.5 
     
IgA 
Number 3/19 1/8 
>0.99 Percentage 15.8 12.5 
     
Light 
chain 





Chemokine receptors expressed on MM PCs play functional roles in MM PC 
migration,6,7,9,17,18 proliferation18,20 and response to chemotherapy22,23 (Chapter 3). 
Notably, CCR1, CCR2 and CXCR4 have previously been shown, by our group and 
others, to be prognostic markers in MM.9,24,25 However, a systematic analysis of the 
association of chemokine receptor expression with survival in newly diagnosed MM 
patients has not been conducted. Here, we investigated the expression of all known 
chemokine receptors in BM PCs from newly diagnosed patients and determined 
whether their expression was associated with overall survival, in order to identify 
chemokine receptors that may play a previously unidentified functional role in MM 
pathogenesis. Of all chemokine receptors expressed in BM MM PCs, apart from CCR1, 
only CCR10 expression was found to be significantly associated with poor prognosis in 
newly diagnosed MM patients.  
 
Our analyses suggest that CCR1 is expressed in almost half (47%) of newly diagnosed 
MM patients by microarray analysis. In accordance with the data presented here, studies 
from our group as well as others have shown that CCR15,9 is expressed in BM MM PCs 
from the majority of patients by flow cytometry. Furthermore, in Chapter 3 we showed 
that CCR1, as assessed by flow cytometry, is expressed in 64.3% (18/28) of newly 
diagnosed MM patients. In line with these studies showing a high proportion of CCR1 
positivity, in Chapter 2 we demonstrated that CCR1 is crucial for the egress of MM PCs 
from the BM to the circulation during dissemination. Our analyses also suggested that 
CXCR4 is expressed in a large proportion (99.3%) of newly diagnosed MM patients by 
microarray analysis. Studies from our group as well as others have shown that 
CXCR45,8,9 is expressed in BM MM PCs from the majority of patients by flow 
cytometry. In line with the consistent expression of CXCR4 observed here, MM PC 
expression of CXCR4 is well-established to be crucial for the homing to and subsequent 
retention within the BM, where BMSC produce high levels of the ligand CXCL12.12-15 
While CCR6 has been shown to be weakly expressed in some MM cell lines,5  and its 
ligand CCL20 able to promote a chemotactic response in these MM cell lines,5 previous 
studies assessing patient-derived BM MM PCs in small numbers of patients (4 to 5 
patients per study)5,8 were unable to detect CCR6 by flow cytometry. These findings are 
in accord with a lack of CCR6 mRNA expression observed in the present study. 
Transcriptome profiling has previously revealed that elevated CX3CR1 expression is 
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highly characteristic of patients with MAF or MAFB translocations (which make up 
approximately 6% of all MM patients),36,37 in accordance with our finding that a 
relatively low number (12.7%) of MM patients express CX3CR1. While the functional 
role for CX3CR1 in MM is unclear, the human MM cell line RPMI-8226 has been 
shown to bind to CX3CL1 in vitro under shear flow, suggesting that it may play a role 
in adhesion to endothelial cells during MM PC homing or dissemination.38 Our studies 
show that CXCR3 is expressed in approximately 30% of patients, which contrasts two 
independent studies which showed that more that 90% of  BM MM PCs from patients 
express CXCR3 expression as assessed  by flow cytometry.11,19 Supporting our findings, 
we also conducted analysis of RNA-sequencing data from the CoMMpass dataset and 
identified that CXCR3 was expressed (FPKM > 1) in MM PCs from 32.9% (251/762) of 
patients (Supplementary Figure 4.1). These data suggesting that the high level of 
CXCR3 expression in previous flow cytometry studies may be due to antibody non-
specificity as the same antibody clone was used in both studies. Previous studies have 
shown that the three CXCR3 ligands, CXCL9, CXCL10 and CXCL11, all induce the 
chemotaxis of MM PCs5,19 and are able to increase the secretion of MMP-2 and MMP-9 
by MM PCs in vitro,19 suggesting that CXCR3 may be involved in MM PC migration 
within the BM. We also observed a high incidence (97.2% of MM patients) of CCR5 
expression. However, previous analysis of protein expression on BM MM PCs showed 
that only 25% (8/29) of patients express CCR5 protein,10 which may be due to receptor 
internalisation or antibody non-specificity. Inhibition of CCR5 has been shown to 
decrease in vivo homing to the BM of CCR5+ 5TMM  MM cells39 suggesting a role in 
dissemination of MM PCs. We also showed that the majority of MM patients (97.2%) 
express CCR2 by microarray, in accordance with previous flow cytometry data which 
demonstrated that CCR2 is expressed in 82% (n=23/28) of MM patients.7 Conditioned 
media from BM endothelial cells (BMECs), which contains CCL2 (ligand for CCR2),17 
is able to induce chemotaxis in MM cell lines and primary MM PCs in vitro,7,17 
suggesting that CCR2 may contribute to migration towards the vasculature. In support 
of this, migration of mouse 5T MM cells towards BMEC conditioned media can be 
blocked using an antibody against CCL2.17 Notably, we demonstrated for the first time 
that CXCR1 is expressed in approximately one third of MM patients. The ligand for 
CXCR1, namely CXCL8, has been shown to induce the chemotaxis and proliferation of 
MM cells in vitro.18 While CXCR4, CCR2, CCR5, CXCR1, CX3CR1 and CXCR3 have 
been previously suggested to have functional roles in MM PCs, our analysis identified 
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no association between elevated BM MM PC expression of these receptors with 
survival of newly diagnosed MM patients.  
 
Nakayama and colleagues have previously reported expression of CCR10 mRNA in a 
panel of 4 human MM cell lines.6 Here we report that CCR10 is expressed in more than 
half of all newly diagnosed MM patients, as assessed by microarray and by qPCR. Our 
microarray analysis also suggested that CCR10 is consistently expressed by normal 
PCs, as well as PCs from MGUS and MM patients. This finding concurs with previous 
microarray studies that showed that normal BM PCs have the highest expression of 
CCR10 of any normal leukocyte subset analysed.40 Additionally, BM CD38++ PCs 
isolated from healthy donors have previously been shown to express an intermediate 
level of CCR10 by flow cytometry.6 CCR10 has also been shown to be predominantly 
expressed on normal circulating IgA PCs found in the peripheral blood41 or in the BM,42 
where they constitute approximately 40% of all BM PCs.42 In this study, we assessed, 
for the first time, CCR10 protein expression in BM malignant PCs isolated from newly 
diagnosed MGUS and MM patients by flow cytometry and found that CCR10 was 
relatively lowly expressed in the majority of MGUS patients but was high in 
approximately one third of MM patients. While in normal PCs CCR10 is predominantly 
expressed by IgA PCs, we found no association between CCR10 expression and 
patients with IgA or IgG paraprotein in our cohort. Importantly, we also conducted 
multivariable analysis and found that elevated expression of CCR10, as assessed by 
microarray, retained its prognostic significance when known high-risk prognostic 
factors, including high-risk cytogenetics, anaemia or β2-microglobulin >5.5mg/L were 
taken into account, suggesting that CCR10 is an independent prognostic factor in MM. 
Furthermore, we showed that elevated BM MM PC CCR10 expression is significantly 
associated with a poorer prognosis in newly diagnosed MM patients. Analysis of 
CCR10 protein expression on BM MM PCs showed similar results, with a trend 
towards high CCR10-expressing patients having a poorer outcome compared with low 
CCR10-expressing patients. Taken together, these data suggest that CCR10 may be a 
novel independent prognostic indicator in MM. 
 
Previous studies suggest that CCR10 may play a role in the pathogenesis of solid 
tumours. For example, CCR10 has been shown to be expressed in 71% (63/89 patients) 
of human primary breast cancer tissue samples, and patients positive for CCR10 
expression also presented with a higher tumour stage and increased incidence of local 
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invasion and lymph node metastasis.43 Furthermore, one of the ligands for CCR10, 
namely CCL27, has been shown to promote migration and Matrigel invasion of a 
CCR10-positive breast cancer cell line in vitro.43 Previous studies have shown that the 
ligands for CCR10, CCL27 and CCL28, also induce the chemotaxis of healthy donor 
BM PCs,6 that CCL27 induces the chemotaxis of some, but not all, MM cell lines 
tested. In contrast, CCL28 was not found to induce the chemotaxis of MM cell lines in 
vitro.44 CCL27 has been shown to be expressed by stromal cell lines and BM stromal 
cell cultures from MM patients, and CCL27 protein levels are increased in the BM of 
MM patients compared with healthy controls.44 Taken together, these data suggest that 
CCL27 may play a role in migration of MM PCs towards stromal cell niches within the 
BM. Notably, elevated levels of CCL27 in BM plasma from MM patients, as assessed 
by ELISA, has been shown to be associated with shorter overall survival of MM 
patients, supporting our data on CCR10 expression.44 As both ligands have been shown 
to have no effect on the proliferation of MM cell lines in vitro,44 we hypothesise that 
CCR10 expression in MM patients promotes increased dissemination of MM PCs, and 
not increased tumour proliferation, leading to poorer prognosis. 
 
While these data raise the possibility that BM CCL27 may play a role in MM 
pathogenesis, the most abundant sources of CCL27 and CCL28 are skin and mucosal 
tissues,41,45-47 suggesting the potential role for CCR10 in driving dissemination to 
extramedullary sites. IgA positive PCs that express CCR10 selectively home to sites of 
high expression of the ligands; namely the oral and olfactory mucosa, salivary gland, 
mammary gland, small and large intestines, female reproductive tract, lungs and the 
trachea where epithelial cells are the primary source of CCL28,41 and the skin where 
epidermal keratinocytes are the primary source for CCL27.46 MM PCs are thought of as 
being strongly dependent on the BM microenvironment for their growth, however in 3-
5% of MM patients at diagnosis dissemination of plasmacytomas to  soft tissues occurs, 
known as extramedullary disease (EMD).48  There is also a high incidence of EMD 
occurrence at relapse, with up to 20% of patients developing EMD lesions as detectable 
by PET scan,49 50 while several studies report that two-thirds of MM patients have 
detectable EMD on autopsy.51-53 The most common sites of extramedullary growth 
occur in skin/soft tissues (30%), spine (25%), liver (21%) and lymph nodes (21%), as 
assessed by PET scans.50 Importantly, many of aforementioned tissues that CCR10-
positive PCs home to including the lungs,50 breast,50 stomach,54 large and small 
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intestine54 and oral cavity50 have been reported in retrospective studies and case series 
as being recurrent sites for EMD. This suggests a potential mechanism whereby 
CCR10-expressing MM PC may disseminate to soft tissue sites via CCL27 and CCL28. 
In support of this, a case study showed that a MM patient who developed EMD in the 
skin at relapse had increased CCR10 expression in MM PCs isolated from the BM at 
relapse compared with diagnosis.55 Furthermore, there was a higher level of CCR10 
mRNA expressed in peripheral blood tumour cells of patients with T-cell 
leukaemia/lymphoma that developed skin lesions (n=10) compared with patients 
without lesions (n=18), as assessed by qPCR.56 In MM, the development of EMD is 
associated with highly aggressive and disseminated disease, reflected by increased 
numbers of circulating tumour cells and poorer prognosis compared with MM patients 
without EMD.57 It can therefore be postulated that the prognostic disadvantage 
conferred by elevated CCR10 expression may, at least in part, be associated  with 
development of EMD.50 It is important to note though that as EMD only occurs in up to 
20% of MM patients49 and, of those, only up to 30% present with skin, soft tissue or 
mucosal EMD,50,58 at either diagnosis or relapse, this is unlikely to be the only 
mechanism underlying the prognostic disadvantage of CCR10 expression in MM 
patients. Future studies are required to determine whether CCR10 plays a role in the 
development of EMD in MM.  
 
Our studies have identified that elevated chemokine receptor CCR10 expression in BM 
MM PCs is associated with poor prognosis in newly diagnosed MM patients. This study 
suggests that CCR10 is a novel independent prognostic marker in MM, but future 
studies on other cohorts of patients are required to confirm these findings.  While the 
role of elevated CCR10 in MM remains to be demonstrated, this study provides a basis 
for future studies to investigate the mechanisms that underpin the adverse prognostic 
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Supplementary Figure 4.1. Expression of chemokine receptors in newly diagnosed 
MM patients.  Gene expression data (FPKM) for CD138-selected BM MM PC isolated 
from newly diagnosed patients (CoMMpass dataset, n=762 patients). Expression less 
than 1 (in grey) was classed as not expressed. Graph depicts median with interquartile 















































































5.1. Clinical implications of targeting CCR1 to prevent tumour 
dissemination in MM 
Multiple myeloma (MM) is characterised by the growth of malignant plasma cells (PCs) 
within the bone marrow (BM).1 MM is preceded by precursor diseases of monoclonal 
gammopathy of undetermined significance (MGUS) and smouldering MM (SMM), 
which are characterised by elevated clonal PCs in the BM, but no evidence of MM-
related pathologies such as hypercalcemia, anaemia, osteolytic lesions and renal 
insufficiency.1 One of the key characteristic features of MM is the presence of multiple 
MRI-detectable tumours throughout the skeleton,1,2 suggesting that MM disease 
progression is dependent on the ability of MM PCs to leave a peripheral lymphoid 
organ, enter the peripheral circulation and disseminate to distal BM sites. In support of 
this, increased numbers of circulating tumour cells, present in the peripheral blood (PB) 
of MGUS and SMM patients, is associated with faster progression to symptomatic 
MM.3-5 With this in mind, it could be hypothesised that targeting dissemination 
provides an opportunity to prevent or slow the progression of disease. In support of this, 
increased numbers of MM PCs in the PB of newly diagnosed MM patients is associated 
with poorer overall survival.6-10 In Chapter 3, CCR1 expression in BM malignant PCs 
was shown to be upregulated in MM patients compared with MGUS patients, as 
assessed by microarray analysis and flow cytometry. As dissemination is one of the key 
drivers of disease development, this suggests that increased CCR1 expression may 
underlie the increased dissemination seen in MM patients compared with MGUS 
patients (as reflected by elevated circulating malignant PC).11 In support of this, a recent 
RNA sequencing study of matched PB and BM MM PCs from 3 MM patients, revealed 
that transcriptional programs related to hypoxia are upregulated in PB MM PCs 
compared with their BM counterparts.12 We have previously shown that CCR1 is the 
most highly upregulated gene when MM cell lines are subjected to hypoxia.13 This may 
suggest a model whereby malignant PC growth within the BM increases BM hypoxia, 
leading to increased CCR1 expression and resulting in malignant PC dissemination and  
progression of disease. This raises the possibility that by inhibiting CCR1 during the 
asymptomatic precursor stages, it may lead to a delay in the transition to active MM.  
 
To the best of our knowledge, the studies in Chapter 2 are the first to show that an 
inhibitor of CCR1 can slow spontaneous MM PC dissemination in vivo. To do this, we 
established mouse models of MM, in which treatment with the small molecule CCR1 
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inhibitor CCX9588, commencing at 3 days post-tumour cell injection, could reduce the 
development of secondary tumours in vivo. However, despite reducing MM PC 
dissemination, mice treated with CCX9588 still developed large secondary tumours 
over the course of treatment. This may be due to early dissemination events which 
occurred prior to initiation of therapy. Alternatively, this may reflect the fact that the 
treatment regimen used was unable to completely block MM PC dissemination. While 
the dose selected was based on pharmacokinetic data suggesting that trough PB levels 
of CCX9588 were sufficient to block CCR1, we did not achieve this dose for some 
animals, suggesting that a higher dose may be required. Furthermore, the concentration 
achieved in the BM may be lower than that achieved in the PB. In addition, the dose 
used was well-tolerated by the animals and could be increased in a subsequent study to 
determine if a complete blockade of dissemination could be achieved with a higher dose 
of CCX9588. Another option would be the development and testing of a CCR1 inhibitor 
with higher potency than CCX9588. In terms of the process of dissemination, 
subsequent homing and establishment of MM PCs is required for the colonisation and 
growth of new secondary tumours. This suggests that combination therapy, using an 
anti-dissemination therapy like CCR1-targeting to prevent circulating MM PC, in 
conjunction with an anti-homing agent to prevent the establishment of secondary 
tumours, may be more effective at slowing disease progression. Previous studies have 
demonsrated that anti-homing agents are effective at slowing homing and thereby 
slowing disease progression in in vivo MM models. Inhibition, either therapeutically or 
using stable knockdown, of molecules involved in adhesion of MM PCs to endothelial 
cells such as P-selectin glycoprotein-1,14 CD44,15 CD16616 and N-cadherin17,18 slowed 
in vivo homing of MM PCs and decreased tumour burden. The studies described in this 
thesis highlight the feasibility of targeting CCR1 to inhibit mobilisation of MM PCs to 
the BM. Further studies are warranted to determine whether an optimised CCR1 
inhibitor dosing, the use of a more potent inhibitor, or combination with anti-homing 
strategies can slow MM disease progression.  
 
While anti-dissemination therapy alone may not be sufficient to slow disease 
progression, it may extend the remission phase post-therapy. Following each round of 
therapy relapse occurs progressively sooner, highlighting the importance of extending 
the remission phase following front-line therapy to achieve better progression-free 
survival rates and extend patient overall survival.19,20 In support of this, there is 
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evidence to suggest that dissemination of therapy-resistant clones may promote the 
development of overt relapse. Multiple studies have shown that time to progression is 
dramatically shorter in patients with detectable circulating PCs at baseline.21,22 For 
example, a lack of detectable cells in the circulation following treatment is associated 
with a significantly longer time to progression (581 days), compared with patients 
whose circulating MM PC numbers increased following therapy (51 days).21 This is 
further supported by studies suggesting that the expansion of MM PC is important for 
disease relapse following therapy,23 with the appearance of focal tumour growth at new 
sites following disease relapse, as detected by MRI, being observed in ~30% of 
patients.23 Lastly, MM tumours are found in disseminated sites other than the BM, 
termed EMD, in approximately 3-5% of MM patients at diagnosis, but this increases up 
to 20% at relapse, suggesting that during the development of relapse, MM PCs are 
disseminating and leading to the development of more aggressive forms of disease.24 
These studies suggest that the recolonisation of the BM at new sites by a dominant, 
therapy-resistant clone is associated with a rapid disease relapse. Therefore, anti-
dissemination agents may potentially be an effective maintenance therapy to extend the 
remission phase and delay relapse. Future studies should address if the use of a CCR1 
inhibitor as a maintenance therapy after front-line treatment can extend progression-free 
survival in in vivo models. Furthermore, studies could be conducted to determine if this 
therapeutic strategy could be harnessed for the treatment of CCR1+ MM patients to 
determine if this leads to an increase in progression-free and overall survival. Patients 
who present with highly aggressive and disseminated disease (as assessed by increased 
circulating tumour cells, EMD and/or indications of plasma cell leukemia (PCL)),25-28 
may stand to benefit the most from anti-dissemination therapy as a maintenance 
therapy.  
 
The findings of this thesis could also have implications for the treatment of other 
cancers. In addition to being frequently expressed in MM tumours, CCR1 is commonly 
expressed in T- and B-cell lymphomas (follicular lymphoma, diffuse large B-cell 
lymphoma, anaplastic large cell lymphoma peripheral T-cell lymphoma),29 acute 
myeloid leukaemia,29 and in tumour biopsies from breast30 and ovarian cancer31 
patients. Additionally, previous studies have shown that expression of CCR1 promotes 
invasion of non-small cell lung cancer,32 hepatocellular carcinoma,33 breast cancer,30 
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ovarian cancer34 and prostate cancer35 cell lines in vitro. Thus, it is possible that CCR1 
inhibitors may be therapeutically useful in preventing metastasis of solid tumours. 
 
5.2. Clinical implications of targeting CCR1 to increase drug sensitivity 
The use of the proteasome inhibitor, bortezomib, as a front-line or maintenance therapy, 
has led to significant improvements in MM patient survival.36 Currently, bortezomib is 
used as an upfront therapy in approximately 50% of MM patients in the USA and 75% 
of patients in Europe, the Middle East, and Africa.37-41 Notably, bortezomib is a 
mainstay of treatment for MM in Australia, where is used as induction therapy in 
approximately 85% of MM patients.42 While responses to bortezomib-based regimens 
are effective in the majority of cases, approximately 20% of patients present with 
intrinsic therapeutic resistance and do not respond to front-line bortezomib-based 
therapy.28 Importantly, these patients have a median overall survival of only 2 years,28 
compared with 6-10 years for other patients.36,43,44 Of those patients who do respond, 
emergence of secondary bortezomib resistance is common, with approximately 40-50% 
of bortezomib-treated patients not responding to retreatment at relapse.45,46 As 
bortezomib is used in second-line regimens in approximately 25% of cases in the 
USA,37 this highlights the importance of achieving a high depth of response to induction 
therapy for long-term patient survival prospects.19,20 In Chapter 3, CRISPR-Cas9 
deletion of CCR1 in MM cells significantly increased their response to initial 
bortezomib therapy, suggesting that CCR1 expression increases intrinsic resistance to 
bortezomib. Furthermore, we also found that patients with either elevated BM MM PC 
CCR1 expression at diagnosis, or with induction of CCR1 expression at relapse, have a 
poorer prognosis compared with patients with low MM PC CCR1 expression 
throughout treatment. It can therefore be postulated that inclusion of a CCR1 inhibitor 
to front-line bortezomib-based therapy might sensitise the tumour cells and achieve a 
greater depth of response in CCR1+ patients. As CCR1 is expressed in more than 70% 
of MM patients13 (Chapter 3), inclusion of a CCR1 inhibitor, if effective, could be 
beneficial for the majority of MM patients.  
 
CXCR4 expressed on MM PCs is critical for homing to and subsequent retention within 
the BM. CXCL12 is abundantly produced by BM stromal cells (BMSCs),47 forming a 
concentration gradient that directs PC entry into the BM, but also increases expression 
of integrin α4β1 on MM PCs to mediate adhesion to BMSCs and retention in the 
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niche.48 In a recent clinical trial, the CXCR4 inhibitor, plerixafor, was used in 
combination with dexamethasone and bortezomib in relapsed/refractory MM patients 
with the aim to decrease adhesion of MM PCs to BMSCs, mobilising MM PCs from the 
protective niche and therefore increase the response to therapy.49 Plerixafor was shown 
to cause at least a partial response to subsequent chemotherapy in 31% (18/58) of 
patients.49 While this suggested a potential increase in response rates, it is important to 
note that treatment with plerixafor also mobilised tumour cells into the blood, which 
may therefore increase the chance of subsequent MM PC dissemination. In this thesis, 
we showed that CCR1 inhibition can slow MM PC dissemination and that loss of CCR1 
expression increases sensitivity to bortezomib therapy. Therefore, treatment with a 
CCR1 inhibitor may prove more effective than plerixafor, as the tumour cells will be 
sensitised to therapy with no added risk of spread to distal sites. This suggests another 
potential therapeutic strategy, whereby CCR1 inhibitors could be used in combination 
with front-line therapy to enhance sensitivity and retained as maintenance therapy to 
limit spread of any treatment-resistant tumours. Future studies are warranted to 
investigate whether this strategy would increase depth of response to therapy and 
subsequently extend progression-free survival.  
 
CCR1 expression has also been shown to be elevated in a chemotherapy-resistant 
prostate cancer cell line,35 suggesting that CCR1 may play a role in the sensitivity of 
other cancer cells to therapeutics. Therefore, CCR1 inhibitors may also increase the 
efficacy of anti-tumour drugs in other cancers and warrants further investigation. 
 
5.3. Use of CCR1 inhibitors in the clinic 
CCR1 plays a role in the activation and trafficking of immune cells, including 
neutrophils, monocytes, and lymphocytes.50 On the basis of these roles, CCR1 inhibitors 
have entered clinical trials for the treatment of a range of inflammatory diseases. For 
example, the CCR1 inhibitors BX471 and AZD-4818 have been assessed in phase II 
trials for multiple sclerosis and chronic obstructive pulmonary disease, respectively; 
however, these studies demonstrated a lack of clinical benefit in these conditions.51 In 
contrast, several studies have demonstrated some efficacy for CCR1 inhibition in the 
treatment of rheumatoid arthritis (RA). The small molecule inhibitor CP-481,715 
entered Phase II clinical trials for the treatment of RA and was found to significantly 
reduce macrophage and other CCR1+ cell infiltration into the synovial membrane of the 
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knee joint.52 Importantly, there was a clinical improvement in a third of treated patients, 
but this did not reach statistical significance in this small study. Similarly, the small 
molecule inhibitor CCX354, an analogue of the inhibitor CCX9588 used in the studies 
described in this thesis, entered Phase II trials for the treatment of RA and showed 
biological and clinical efficacy.53 In contrast, MLN3897 also entered a Phase II proof-
of-concept study for the treatment of RA but was no longer pursued as it did not show 
discernible activity, possibly due to insufficient CCR1 blockade.54 Importantly, CCR1 
targeting has been shown to be generally well tolerated in all of the above-mentioned 
clinical trials.52-55   
 
In the treatment of MM, a number of CCR1 inhibitors have shown promise in pre-
clinical mouse models with regard to the prevention of the development of severe 
osteolytic lesions.56,57 Osteolytic lesions are a major debilitating symptom of MM,58,59 
associated with bone pain and pathological fractures, and prevention of the formation of 
overt lesions would be extremely beneficial for patients. CCR1 is expressed on 
osteoclasts, with studies showing that CCL3 produced by MM PCs activates CCR1 on 
pre-osteoclasts to promote their differentiation into mature osteoclasts and thereby 
increasing tumour associated bone destruction.60,61 Notably, inhibition of CCR1 has 
previously been demonstrated to inhibit tumour associated bone loss in mouse models 
of MM. In a MM mouse model, the CCR1 inhibitor MLN3897 was shown to decrease 
osteoclast formation and activity.62 CCR1 inhibition using the small molecule inhibitor 
CCX721 resulted in a reduction in the number of osteoclasts per bone surface compared 
with controls in an MM mouse model, a reduction that was comparable to using the 
bisphosphonate zoledronic acid.56 Furthermore, this study showed that CCR1 inhibition 
reduced tumour burden in mice compared with controls. Similarly, a study by Menu and 
colleagues showed that treatment of mice with the CCR1 inhibitor BX471 reduced the 
number of osteolytic lesions and tumour burden compared with controls.57 Notably, 
these in vivo studies utilised the MM cell lines 5TMM and 5TGM1 that express very 
little or no CCR1 on their cell surface but produce CCL3.56,57 Therefore, the effects on 
tumour burden are suggested to be secondary to inhibition of osteoclasts, which are a 
known source of MM PC growth factors such as IL-6.63 Taken together with previous 
studies, the findings presented in this thesis suggest that targeting of CCR1 may be 
beneficial to target multiple aspects of MM pathogenesis: reducing dissemination and 
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tumour burden, reducing the severity of osteolytic lesions, and potentially increasing the 
efficacy of bortezomib.  
 
5.4. CCR10 as a novel prognostic factor in MM  
MM PCs have been shown to express a variety of chemokine receptors and express a 
range of chemokine ligands,64 but the role of many of these receptors as therapeutic 
targets or biomarkers in MM remains unclear. Our previous study showed that elevated 
BM MM PC CCR1 expression was associated with poorer prognosis of newly 
diagnosed MM patients.13 In this thesis, several molecular mechanisms that may be 
involved in the prognostic disadvantage of CCR1 in MM were identified. To further 
investigate the role of chemokine receptors in MM and identify other receptors which 
may play a role in MM pathogenesis, a systematic analysis of the association between 
MM PC chemokine receptor expression prior to therapy and survival in MM patients 
was conducted (Chapter 4). These analyses identified that elevated CCR10 expression is 
associated with poorer prognosis of newly diagnosed MM patients. Furthermore, 
eCCR10 expression, as assessed by microarray, was not associated with any known 
prognostic markers. These studies suggest that CCR10 is a novel independent 
prognostic marker in MM, although this requires validation in an independent patient 
cohort.  
 
While MM PCs are thought of as being strongly dependent on the BM 
microenvironment for their growth, the growth of plasmacytomas in soft tissues, known 
as EMD, occurs in about 3-5% of MM patients at diagnosis,24 with the most common 
sites of growth occurring in skin/soft tissues (23-30%), kidney (27%), spine (14-25%), 
lymph nodes (17-21%) and liver (8-21%), as assessed by PET scans.65,66 Furthermore, 
in up to 20% of patients, EMD develops at relapse,24 with sites of common growth 
being liver (34%), spine (23%) and skin/soft tissues (14%), as assessed by PET scans.65 
Importantly, patients with EMD often present with highly aggressive disease and have a 
poorer prognosis compared with MM patients without EMD.27 Despite the need for 
targeted therapeutics to prevent the development of EMD, what signals expressed 
within soft tissues enables MM PC dissemination to these sites remains unclear.  The 
ligands for CCR10, CCL27 and CCL28, are highly expressed in and dictate the 
infiltration of CCR10+ inflammatory cells to the skin and mucosal surfaces, 
respectively.67 Furthermore, CCL27 has been shown to induce the chemotaxis of MM 
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cell lines in vitro.68,69 These studies suggest that extramedullary spread of CCR10+ MM 
PCs to the skin and mucosal surfaces may be mediated in part by CCR10 and its 
ligands, identifying one potential mechanism underpinning the prognostic disadvantage 
of elevated CCR10 expression in MM patients. While further investigation of this 
mechanism is needed, inhibition of CCR10 may represent a novel targeted therapy for 
the prevention skin and mucosal surface EMD development in MM. Furthermore, while 
PET-detectable skin and mucosal infiltration is generally a rare event in MM patients, 
being observed in less than 2% of MM patients,65 the actual frequency of dissemination 
to these sites may be more frequent than is commonly identified in studies that rely on 
imaging or clinical diagnosis to identify EMD. For example, while lung EMD is 
reported in less than 1% of MM patients clinically, it has been observed in 3%-15% of 
all MM patients on autopsy,70-73 suggesting that the true contribution of soft tissue 
infiltration of MM PCs may be higher than realised. Future studies should investigate 
the association of CCR10 expression and incidence of EMD in patients and determine if 
CCR10 drives MM PC dissemination and EMD development in vivo.  
 
5.5. Concluding Remarks 
While the majority of MM patients currently have a median overall survival of 6-10 
years,36,43,44 approximately 20% of MM patients have a median overall survival of only 
2 years.28 These patients are classified as high-risk and are characterised by poor 
cytogenetic features, elevated numbers of circulating tumour cells and poorer responses 
to front-line therapy leading to shorter time to relapse.28 This suggests that both intrinsic 
therapeutic resistance and increased circulating tumour cells contribute to poorer 
prognosis in MM. We have previously shown that elevated CCR1 expression is 
associated with increased numbers of circulating tumour cells and poorer prognosis in 
newly diagnosed MM patients.13 This thesis definitively demonstrated that CCR1 is 
crucial for the egress of MM PCs from the BM to the circulation in MM mouse models. 
Furthermore, we are the first, to our knowledge, to show that targeting of dissemination 
in vivo is feasible, with results indicating that therapeutic inhibition of CCR1 slowed the 
dissemination of MM PCs. While these studies suggest that anti-dissemination therapy 
alone may not be effective at slowing disease progression, CCR1 inhibitors may be 
beneficial as a maintenance therapy to prevent the dissemination of therapy-resistant 
clones in CCR1+ patients. We further demonstrated that CCR1 expression decreased the 
sensitivity of MM PCs to bortezomib therapy, suggesting that CCR1 inhibitors may 
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synergise with bortezomib to increase anti-tumour effects. Taken together, our findings 
on the role of CCR1 in dissemination and therapeutic resistance coupled with previous 
studies showing that CCR1 inhibitors can reduce the development of osteolytic lesions 
in mouse models of MM56,57,62 suggest that inhibition of CCR1 may be an effective 
strategy to target multiple aspects of MM pathogenesis.  
 
This thesis further investigated the association of chemokine receptors expressed in 
patient-derived MM PCs with patient survival to identify receptors that play a role in 
MM pathogenesis and/or potential biomarkers. Using patient specimens and 
interrogation of large patient datasets, this thesis showed that elevated CCR10 
expression in BM MM PCs is associated with poorer prognosis of newly diagnosed MM 
patients. CCR10 expression did not correlate with known prognostic markers, 
suggesting that CCR10 may represent a novel independent prognostic marker in MM, 
although this requires confirmation in an independent cohort of patients. This thesis 
research has provided a basis for future studies to determine the mechanisms underlying 
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